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1 Summary 
Brain endothelial capillary cells form the blood-brain barrier (BBB), a highly selective 
membrane between the peripheral blood and the central nervous system. The main 
functions of the BBB are to protect the brain tissue by preventing the entry of toxic 
compounds and to supply it with nutrients in order to assure proper function. Tight 
junctions are the key elements for the establishment of a tight barrier and seal the 
intercellular gaps against passive diffusion of hydrophilic compounds. A second 
important characteristic of the brain capillary endothelial cells are transport proteins that 
prevent brain penetration of their substrates by pumping them back in the blood. These 
compounds include a series of clinically used drugs. Important drug efflux transporters 
located at the BBB are P-glycoprotein (P-gp), the breast cancer resistance protein 
(BCRP) and the family of multidrug resistance proteins (MRP).  
During drug development, the question of whether a drug candidate reaches the brain 
tissue is of great importance. Therefore, models are needed to predict the BBB 
permeability of new compounds. In the past, in vitro models have been developed to 
address this question. These models include isolated brain capillaries, isolated primary 
brain capillary endothelial cells and BBB cell lines of various origins. A major problem 
encountered with these cell lines was an insufficient paracellular resistance.  
Recently, the hCMEC/D3 cell line was generated by immortalizing primary human brain 
endothelial cells. In culture this cell line shows a morphology that closely resembles to 
primary cells, forms tight monolayers and expresses BBB markers such as chemokine 
receptors, tight junctional molecules and ATP binding cassette (ABC)-transporters. 
The aim of this thesis was to evaluate the hCMEC/D3 cell line as an in vitro model of the 
human BBB to study 1) permeability properties including para- and transcellular diffusion 
as well as active transport 2) the influence of endo- and exogenous factors on the 
paracellular permeability and 3) the regulation of breast cancer resistance protein and P-
glycoprotein by pro-inflammatory cytokines. 
The first study describes the characterization of the hCMEC/D3 cells as an in vitro model 
of the human BBB for permeability studies (section 5). The ability of the cells to allow 
discrimination between para- and transcellular diffusion was investigated by measuring 
the transport of a series of compounds with different physicochemical properties. A ratio 
of 2.8 was observed when comparing the permeabilities of the compounds with the 
highest and the lowest diffusion rate. The passive permeability of sucrose could be 
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reduced significantly by replacing fetal calf serum with human serum. Furthermore, 
quantitative mRNA expression of the ABC-transporters P-gp, BCRP, MRP1, MRP2, 
MRP3, MRP4, MRP5 as well as the human transferrin receptor (hTfR) was shown. 
Protein expression of P-gp, BCRP and the hTfR was detected and functional activity of 
P-gp, BCRP and the MRPs was investigated in efflux experiments. Furthermore, 
bidirectional P-gp transport activity was observed. 
In a second project the impact of endo- and exogenous factors on the paracellular 
permeability of hCMEC/D3 monolayers was assessed, since it is know that the molecular 
assembly of tight junctions depends on the surrounding milieu (section 6). Based on 
reports in the literature, the cells were incubated with a variety of compounds that 
included anti-inflammatory drugs, growth factors and antioxidants. The effects on the 
monolayer tightness of hCMEC/D3 were investigated by measuring the transport of 
sucrose, a paracellular permeability marker. N-acetylcystein (NAC), atorvastatin and 
sodium nitroprusside (SNP) reduced the sucrose permeability significantly, and slightly 
increased zonula occludens protein (ZO-1) expression. Additionally, NAC and SNP 
reduced the generation of reactive oxygen species (ROS), which have been reported to 
disrupt the assembly of tight junctions.    
The effect of the pro-inflammatory cytokines IL-1β, IL-6 and TNF-α on the expression and 
activity of the ABC-transporters BCRP and P-gp was investigated in the hCMEC/D3 cell 
line (section 7). IL-1β, IL-6 and TNF-α, which are know to be elevated during various 
diseases, suppressed significantly BCRP mRNA expression. In addition, BCRP activity 
was reduced under the influence of all tested cytokines, as shown by efflux experiments. 
P-gp mRNA levels were slightly reduced by IL-6 but significantly increased after TNF-α 
treatment. TNF-α also increased the protein expression of P-gp. This in vitro study 
indicates that expression levels of BCRP and P-gp at the BBB might be altered during 
acute or chronic inflammation, resulting in a changed brain penetration of their 
substrates.  
In an isolated project, the pharmacokinetics and pharmacodynamics of increasing oral 
doses of the satiety peptides GLP-1 and PYY3-36 were assessed in healthy male 
volunteers. Oral administration of either peptide induced a rapid and dose-dependent 
increase in plasma drug concentrations. Oral administration of GLP-1 induced a potent 
effect on insulin release and both peptides suppressed ghrelin secretion. In conclusion, 
this study showed, for the first time, that satiety peptides such as GLP-1 and PYY3-36 
can be orally delivered safely and effectively in humans. 
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2 Aim of the thesis 
The main goal of the present thesis was a further characterization and improvement of a 
new in vitro model of the human blood-brain barrier. The blood-brain barrier is a selective 
barrier between the blood and the central nervous system limiting the brain penetration of 
xenobiotics as well as a series of clinically used drugs. While tight junctions prevent 
hydrophilic compounds from passively diffusing the expression of drug transporters 
enables active efflux of their substrates. During drug development it is of great 
importance to have an in vitro tool that allows prediction of the brain penetration of drug 
candidates. The recently developed human cell line hCMEC/D3, obtained from isolated 
human brain capillary endothelial cells is a promising model. Compared to primary cells, 
a blood-brain barrier cell line offers the advantage of a higher experimental throughput. 
However an extensive evaluation is needed regarding important blood-brain 
characteristics, such as the formation of a tight monolayer and the functional expression 
of drug efflux transporters. Our studies were focused on permeability properties including 
para- and transcellular diffusion as well as on the expression, functionality and regulation 
of ABC-transporters. Therefore this thesis is divided into the following sections: 
 
• Characterization of the hCMEC/D3 cells with respect to passive and active transport. 
• Improvement of the model towards lower paracellular permeability under influence of 
endo- and exogenous factors. 
• Regulation of breast cancer resistance protein and P-glycoprotein by pro-
inflammatory cytokines. 
 
In an isolated project the oral pharmacokinetics and pharmacodynamics of the satiety 
hormones glucagon-like peptide-1 (GLP-1) and peptide YY3-36 (PYY3-36) using a novel 
application form was investigated. 
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3 Introduction 
3.1 History of the blood-brain barrier 
The discovery of the blood-brain barrier (BBB) dates to the end of the 19th century. Paul 
Ehrlich was the first to describe a barrier between the blood and the central nervous 
system (CNS). After injecting a dye into the systemic circulation of rats, he observed that 
the brain tissue and the spinal cord remained unstained (Ehrlich 1885). Ehrlich himself 
did not believe in the theory of a barrier and suggested an insufficient affinity of the dye 
to the CNS. Some years later his student Edwin Goldman demonstrated the existence of 
a barrier by staining the CNS with the same dyes injected into the subarachnoid space 
(Goldmann 1909). Lewandowski was the first to coin the term the “blood-brain barrier” 
(Lewandowski 1900). In 1967, Reese and Karnovsky revealed the basic structural 
characteristics of the BBB by electron microscopy. They showed that the capillary 
endothelial cells are responsible for the tightness of the barrier by forming intercellular 
tight junctions (TJ) (Reese and Karnovsky 1967). After Betz et al. had established the 
first in vitro system of the BBB using isolated brain capillary endothelial cells (BCEC) 
(Betz et al. 1980) many in vivo and in vitro models of the BBB were established.  
3.2 Physiological functions of the BBB 
The two main functions of the BBB are the protection of the brain from blood-bourne toxic 
compounds and the maintenance of CNS homeostasis. The BBB prevents almost all 
large hydrophilic compounds from entering the brain, whereas many lipophilic 
compounds and gases can freely diffuse across the membrane. Furthermore, BCEC 
express drug transporters which limit the brain penetration of their substrates (mainly 
lipophilic drugs and xenobiotics) by transporting them back into the peripheral blood 
(Banks 1999). Despite these protective functions, the BBB supplies the brain with the 
necessary nutrients, such as glucose and amino acids, by active transport processes. In 
addition, the BBB regulates the osmotic pressure in the CNS in order to ensure correct 
function (Drewes 2001). 
3.3 Anatomy of brain capillaries 
Brain capillaries are the smallest vessels of the human circulation (3-7 µm diameter) with 
a total length of 600-650 km and a surface area of 20 m2 (Pardridge 2003). Different cell 
types, including endothelial cells, astrocytes pericytes and neurons build up these 
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capillaries. The cellular complex is named the “neurovascular unit” and regulates the 
cerebral bloodflow by interacting with smooth-muscle cells (Abbott et al. 2006).  
 
Figure 1 Cellular constituents of the blood–brain barrier. The barrier is formed by capillary 
endothelial cells, surrounded by basal lamina and astrocytic perivascular endfeet, pericytes and 
microglia (adapted from (Abbott et al. 2006)).  
In comparison to peripheral endothelial cells they are characterized by a high 
mitochondrial content (Oldendorf et al. 1977), their lack of fenestration (Fenstermacher et 
al. 1988) and a minimal pinocytotic activity (Sedlakova et al. 1999). Furthermore, BCEC 
express TJ that seal the paracellular passage of hydrophilic compounds. The endothelial 
cells grow on a basal lamina, a membrane with a complex structure of collagen and 
proteins such as laminin, fibronectin and other extracellular-matrix proteins (Goldstein 
and Betz 1983). The endothelial cells share the basal lamina with surrounding pericytes, 
neurons and endfeet of the astrocytes.  
Since pericytes and astrocytes are in close contact with the endothelial cells, it was 
assumed that they could induce specific features of the BCECs. In different in vitro 
models it was demonstrated that astrocytes improve the barrier function and alter the 
expression of drug transporters such as P-glycoprotein (P-gp) or the glucose transporter 
(GLUT1) by releasing soluble factors, which interact with the endothelial cells (Schinkel 
1999; McAllister et al. 2001). An inducing effect towards more BBB-like properties was 
6 
shown for transforming growth factor (TGF), glial-derived neurotrophic factor (GDNF) and 
basic fibroblast growth factor (bFGF). As well as astrocytes, pericytes, which wrap 
around the endothelial cells, have more recently been shown to be responsible for the 
maturation of an intact BBB (reviewed in (Abbott et al. 2006)). It was suggested that 
pericytes stabilize the structure of endothelial brain capillaries by suppressing apoptosis 
of the endothelium (Ramsauer et al. 2002) 
3.4 Tight junctions 
The key structures of the BBB are the TJ. As seen by freeze-fracture images, TJ are 
assembled by a complex of intramembranous strands, which tighten the gaps between 
the cells (Nagy et al. 1984). The TJ consist of three integral membrane proteins 
(occludin, claudin and junctional adhesion molecules (JAM)), which are linked to different 
cytoplasmic accessory proteins, including the zonula occludens (ZO) proteins ZO-1, ZO-
2, ZO-3 and cingulin. TJ are known to prevent the paracellular passage of small 
molecules and even ions such as Na+ and Cl-. This property leads to high 
transendothelial electrical resistances (TEER) of 1,500-2,000 Ω cm2 in vivo (Butt et al. 
1990). 
The first integral membrane protein to be discovered was the 65 kDa occludin (Furuse et 
al. 1993). The structure of occludin consists of four transmembrane domains, a long 
cytoplasmic COOH terminus and a short cytoplasmic NH2 terminus. Occludin is directly 
linked to the ZO proteins by its cytoplasmic domains (Hirase et al. 1997). Studies indicate 
that occludin does not directly exert paracellular tightness but regulates the permeability 
of TJ depending on its phosphorylation status (reviewed in (Wolburg and Lippoldt 2002)).  
So far, 24 members of the claudin family are known (Ballabh et al. 2004). These 22 kDa 
phosphoproteins have four transmembrane domains and bind with their COOH terminus 
to cytoplasmic proteins such as ZO-1, ZO-2 and ZO-3 (Furuse et al. 1998). By binding 
homotypically to each other, claudins are assumed to seal the TJ (Furuse et al. 1999). At 
the BBB claudin-3 (formerly classified as claudin-1) and claudin-5 appear to be 
responsible for the low paracellular permeability (Morita et al. 1999; Liebner et al. 2000; 
Liebner et al. 2000; Lippoldt et al. 2000). 
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Figure 2 Molecular organization of a tight junction (adapted from (Neuwelt et al. 2008)) 
The JAM are 40 kDa proteins having a single transmembrane domain and an 
extracellular domain with two immunoglobulin-like loops formed by disulfide bonds 
(Martin-Padura et al. 1998). In brain endothelial cells JAM-1, JAM-2 and JAM-3 are 
present being involved in the maintenance of the TJ (Palmeri et al. 2000; Aurrand-Lions 
et al. 2001).  
The integral membrane proteins are anchored to cytoplasmic accessory proteins, mainly 
ZO-1, ZO-2 and ZO-3. The ZO molecules and cingulin are membrane-associated 
guanylate kinase-like protein (MAGUKs). They share defined core regions (a SH3, a 
guanylate cyclase and a PDZ domain), which enables them to be involved in signal 
transduction and anchoring the transmembrane TJ proteins to the cytoskeleton (Furuse 
et al. 1994; Itoh et al. 1999; Ebnet et al. 2000). 
3.5 Transport at the blood-brain barrier 
The expression of transport proteins is a major characteristic of the BCEC forming the 
BBB. Since the BBB is impermeable for nutrients, which are essential for the brain 
function, several transport systems are present in BCEC, including GLUT1, several 
amino acid transporters, nucleoside and monocarboxylic acid transporters (Drewes 
2001).  
8 
Besides uptake transporters different families of drug efflux transport proteins are 
expressed in BCEC. These transporters limit their substrates including drugs, toxic 
metabolites or dietary toxins from brain penetration by an active efflux process (de Boer 
et al. 2003). The following sections are focused on the efflux transporters since they are 
an important characteristic of the BBB. 
 
Figure 3 Schematic diagram of drug transporter expression in human brain endothelial capillary 
cells. The membrane localization of OATP-A is unclear. 
3.5.1 ABC-transporter 
ABC-transporters are one of the largest of all protein families, comprising 48 genes that 
are classified into seven subfamilies according to their gene structure and amino acid 
alignment (Dean et al. 2001). They are integral membrane proteins that use the energy 
of ATP hydrolysis for translocation of their substrates across membranes against high 
concentration gradients. The main function of ABC-transporters is the protection of the 
body from natural toxins or xenobiotics. Therefore, they are expressed at sites with 
excretory functions (liver and kidney) and at barriers that limit entry of toxins (BBB, blood-
testis barrier, gastro-intestinal tract) (Schinkel and Jonker 2003; Loscher and Potschka 
2005).  
P-glycoprotein  
P-glycoprotein (ABCB1, P-gp) is a 170 kDa phosphorylated glycoprotein with two 
homologous halves including 12 transmembrane domains and two ATP binding sites in 
total (Jones and George 2000). There exist two type
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MDR2 genes. At the human BBB only P-gp encoded by MDR1 is present (Demeule et al. 
2002).  
P-glycoprotein was initially described in the field of cancer mediating multidrug resistance 
(MDR) by ATP-driven efflux of chemotherapeutics (Biedler and Riehm 1970). P-gp has a 
broad substrate specificity including anticancer drugs, immunosuppressive agents, 
corticoids, opioids, HIV protease inhibitors, antipsychotic drugs, antiepileptic drugs, etc 
(reviewed in (Loscher and Potschka 2005). It was also the first transporter to be 
discovered at the human BBB (Cordon-Cardo et al. 1989; Thiebaut et al. 1989). By 
confocal and electron microscopy several studies show an expression of P-gp at the 
luminal membrane of the BBB of various species (Jette et al. 1993; Demeule et al. 2002). 
In mdr1(-/-) knock-out mice 10- to 100-fold elevated brain levels of P-gp substrates such 
as ivermectin or vinblastine were found, demonstrating the impact of P-gp in vivo 
(Schinkel and Jonker 2003). Clinical drug-to-drug interactions mediated by P-gp at the 
BBB in humans were described for the P-gp substrates cyclosporine A and verapamil. 
Verapamil brain levels were significantly increased in the presence of cyclosporine A 
(Sasongko et al. 2005).   
BCRP 
The breast cancer resistance protein (ABCG2, BCRP) is a 72 kDa half-transporter with 6 
transmembrane segments that forms functional homodimers. BCRP was first discovered 
in a therapy-resistant breast cancer cell line (Doyle et al. 1998). Only recently was it 
discovered to be expressed at the apical membrane in endothelial cells of the BBB of 
pigs and humans (Cooray et al. 2002; Eisenblatter and Galla 2002; Lee et al. 2005). In 
addition, BCRP is expressed in the placenta, colon and small intestine (Loscher and 
Potschka 2005). BCRP substrates include anticancer drugs such as mitoxantrone, 
daunorubicin, doxorubicin, topotecan and epirubicin, carcinogens and dietary toxins (van 
Herwaarden et al. 2003; Han and Zhang 2004). The role of BCRP in vivo is controversial. 
In mdr1 knock-out mice the brain uptake of mitoxantrone was increased in the presence 
of the P-gp and BCRP inhibitor elacridar, giving first functional evidence of BCRP 
mediated transport at the BBB (Cisternino et al. 2004). However, a different study reports 
no altered mitoxantrone brain levels in Bcrp knock-out mice (Lee et al. 2005). 
MRPs 
The proteins of the multidrug resistance protein (MRP, ABCC) family also belong to the 
superfamily of ABC-transporters. 12 MRPs are known to be members of the ABCC 
family. They are involved in the transport of anionic to neutral drugs such as anticancer 
drugs, anti-HIV drug and glutathione, glucuronide and sulphate conjugates. Although P-
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gp substrates are generally cationic molecules there is a significant overlap of substrate 
specificity with MRPs (Borst et al. 2000; Loscher and Potschka 2005).  
In bovine BCECs mRNA of MRP1, MRP4, MRP5 and MRP6 are present as well as low 
levels of MRP2 (Zhang et al. 2000; Berezowski et al. 2004). A different study also 
revealed the expression of MRP2 at the luminal side of brain capillaries of rat and 
porcien origin (Miller et al. 2000). However, only limited data is available on the 
expression of the MRPs at the human BBB. High mRNA levels of MRP1 compared to 
MRP2, MRP3 and MRP5 are reported (Dombrowski et al. 2001). A different study 
revealed MRP1, MRP4 and MRP5 expression at the protein level, whereas MRP2, 
MRP3 and MRP6 were not detectable (Nies et al. 2004). In bovine and human BCEC, 
MRP1 and MRP5 are expressed at the apical membrane, whereas MRP4 is equally 
expressed at both membranes (Zhang et al. 2000; Nies et al. 2004).  
So far little is known about the impact of the MRPs in vivo. MRP1 knock-out mice 
showed no altered brain penetration of etoposide (Cisternino et al. 2003). However, the 
extrusion rate of an endogenous estradiol-glucuronide was reduced after intracerebral 
injection indicating MRP1 being involved in the excretion of metabolites from the brain, 
rather than in drug efflux from blood-derived compounds (Cisternino et al. 2003; 
Sugiyama et al. 2003). In rats lacking mrp2 phenytoin brain levels were increased, 
indicating that mrp2 prevents phenytoin from penetrating the brain (Potschka et al. 2003). 
3.5.2 Solute carriers 
The superfamily of solute carriers (SLC) contains a multitude of genes that are divided 
into 43 families coding transport proteins (Hediger et al. 2004). These proteins act 
passively as ion-coupled transporters, facilitated transporters or exchangers. At the BBB 
transporters of the SLCO/SLC21A and SLC22 family are involved in efflux processes.  
Brain capillaries of the rat express the organic anion transporting polypeptides (Oatp) 
Oatp1a4 (Slco1a4), Oatp1a5 (Slco1a5) and Oatp1c1 (Slc1c1), at the luminal and 
abluminal membrane, where they are involved in the transport of amphiphatic organic 
anions such as bile acids and steroid conjugates (Kusuhara and Sugiyama 2005). Only 
one human isoform, OATP1A2 (SLCO1A2), with a high homology to the rat isoforms is 
known and expressed at the human BBB. However, its membrane localization as well as 
its impact in vivo remains unclear (Gao et al. 2000).  
Members of the SLC22 family that are known to be expressed at the human BBB are the 
organic anion transporter (OAT3, SLC22A8) and the organic cation/carnitine transporter 
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(OCTN2, SLC22A3). OAT3 is expressed at the basolateral membrane of the rat BBB 
whereas its membrane localization at the human BBB remains unclear (Mori et al. 2004). 
Substrates of OAT3 include para-aminohippuric acid, benzylpenicillin and homovanillic 
acid (Kusuhara and Sugiyama 2005). OCTN2 is a sodium dependent carnitine 
transporter, which is expressed amongst others at the BBB of different species (Miecz et 
al. 2008). Since mice lacking this transporter show reduced brain concentrations of 
acetyl-carnitine a luminal localization is suggested (Kusuhara and Sugiyama 2005).    
3.5.3 Receptor-mediated transcytosis 
Compounds of high molecular weight, such as peptides of high molecular weight, are too 
large for transport by carrier proteins. Such molecules are translocated across the BBB 
by receptor-mediated transcytosis. Therefore, BCEC express receptors for ligands such 
as transferrin or insulin. The receptors are internalized by clathrin coated pits, forming 
early endosomes that are transported to the lysosomes, where their content can be 
released. The receptors are shuttled back to the plasma membrane by membrane 
vesicles (de Boer et al. 2003).  
An important receptor at the BBB is the transferrin receptor (Jefferies et al. 1984). It is 
involved in the endo- and exocytosis of iron loaded transferrin. After binding of Fe2+-
transferrin to the TfR, endocytosis via clathrin-coated pits occurs (Li and Qian 2002). In 
order to deliver drugs that cannot cross the BBB to brain tissue, the transferrin system 
was used for targeting experiments. Liposomes loaded with daunomycin were coupled to 
antibodies directed against the TfR (Huwyler et al. 1996). After injecting these 
immunoliposomes into rats, significantly increased daunomycin brain levels were 
measured, compared to the free drug (Schnyder et al. 2005). 
3.6 Models of the blood-brain barrier 
During the process of drug development the question of whether new drug candidates 
cross the BBB is of great importance. CNS active compounds have to pass the BBB in 
order to reach their targets, whereas brain penetration might not be desirable for 
peripherally acting drugs that cause CNS-related adverse reactions. Therefore, there is a 
need for models showing the main BBB characteristics such as low paracellular 
permeability, expression and functional activity of transport systems in order to allow a 
precise and reliable prediction of drug permeability. During the past years many different 
in vitro models have been developed. 
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3.6.1 Isolated brain capillaries 
Isolated brain capillaries of bovine origin were described as the first in vitro model of the 
BBB (Siakotos and Rouser 1969). Since then, many models have been reported using 
fragments of brain capillaries of different origins such as pigs, rat, mice or humans. 
These models were successfully used for drug accumulation or binding studies as well 
as for assessments of transporter activity and gene expression (Pardridge et al. 1985; 
Gutmann et al. 1999; Torok et al. 2003; Banks et al. 2005; Hartz et al. 2006). However, 
permeability studies are difficult to perform, as drugs cannot be applied to the apical side 
of the endothelial cells. Therefore, in vitro models using cultures of isolated primary 
BCEC were developed. 
3.6.2 Isolated primary BCEC 
By an isolation process endothelial BCEC are obtained, which can be seeded on 
permeable membranes, where the cells form a polarized monolayer (Cecchelli et al. 
1999). This setup allows bidirectional permeability measurements. Depending on the 
origin of the cells, the culturing conditions and the measuring setup high electrical 
resistances can be observed, which indicate low ion fluxes. Transport of paracellular 
marker compounds such as inulin or sucrose gives more information about the tightness 
of the monolayer against small molecules. In addition, the functional activity of uptake 
and efflux transporters can be determined. By isolating cells of porcine and bovine origin, 
high yields of endothelial cells can be obtained, which meet the requirements for 
permeability studies (Bowman et al. 1983; Audus and Borchardt 1986; Franke et al. 
1999; Gutmann et al. 2002). In addition, models of rat (Perriere et al. 2005) and human 
(Megard et al. 2002) origin have been published. Some groups developed co-culture 
systems using isolated astrocytes growing in the same well as BCEC. These studies 
demonstrated that astrocytes can induce the barrier properties of the BCECs (Cecchelli 
et al. 1999; Megard et al. 2002). The quantitative expression of drug transporters in 
isolated BCEC is a subject much debated. It has been shown that MRP1 is highly up-
regulated compared to isolated capillaries in rat and porcine BCEC (Gutmann et al. 1999; 
Regina et al. 1999), whereas P-gp expression is reduced in cultured BCEC (Regina et al. 
1999). A limitation of primary cell culture models is the laborious and time-consuming 
isolation process that does not allow high throughput studies. In addition, ethical 
considerations limit the availability of cells of human origin, and the problems of potential 
inter-species differences arise if experiments are performed using cells of non-human 
origin.  
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3.6.3 BBB cell lines  
In order to obtain in vitro BBB models, which consume fewer resources and are easier to 
handle, cell lines of different origins were generated. These cell lines were obtained by 
transfection of primary BCEC with immortalizing genes, such as the SV40 T antigen, 
enabling cell division without degeneration of the phenotype for a certain number of 
passages. Among the cell lines used mostly are the rat cell lines RBE4 (Roux et al. 1994) 
and GPNT (Regina et al. 1999), the MBEC (Tatsuta et al. 1992) and the commercially 
available b.End3 (Omidi et al. 2003) of murine origin and the human cell lines NKIM-6 
(Ketabi-Kiyanvash et al. 2007) and BB19 (Prudhomme et al. 1996; Kusch-Poddar et al. 
2005). In contrast to cultures of primary BCEC, cell lines generally fail to form tight 
monolayers with sufficiently low paracellular tightness. Recently, the human brain 
capillary endothelial cell line hCMEC/D3 has been developed (Weksler et al. 2005). The 
hCMEC/D3 cells show a stable phenotype, the expression of endothelial cell markers, TJ 
molecules, chemokine receptors and ABC-transporters. Furthermore, the paracellular 
permeability is much lower compared to other cell lines. These characteristics make the 
hCMEC/D3 an interesting tool for permeability studies. 
 
14 
4 General Methods 
4.1 Cell culture 
Immortalized human brain capillary endothelial cells (the hCMEC/D3 cell line) were 
obtained under license from INSERM, France. The original brain endothelial cells of 
passage 0 used for the generation of the cell line were isolated from human brain tissue 
following surgical excision of an area from the temporal lobe of an adult female with 
epilepsy. The hCMEC/D3 cell line had been immortalized by lentiviral transduction of the 
catalytic subunit of human telomerase and SV40-T antigen into very early cultures of 
adult human brain endothelial microvascular cells (Weksler et al. 2005). The hCMEC/D3 
cells used for the experiments were between passage 25 and 35. All culture ware was 
coated with rat-tail collagen type I solution at a concentration of 0.1 mg/ml and was 
incubated for 1 h at 37°C. For culturing, the cells were seeded in a concentration of 
27000 cells/cm2 and grown in EBM-2 medium supplemented with VEGF, IGF-1, EGF, 
basic FGF (bFGF), hydrocortisone, ascorbate, penicillin-streptomycin and 2.5% FCS, as 
recommended by the manufacturer. For functional assays the cells were grown in a 
growth-factor-depleted medium (EBM-2 supplemented with bFGF 1 ng/ml, 2.5% FCS, 
0.55 µM hydrocortisone, 10 mM HEPES, and penicillin-streptomycin), in the following 
referred to as the assay medium. Cells were cultured in an incubator at 37°C with 5% 
CO2, 95% fresh air and saturated humidity. Cell culture medium was changed every 2 to 
3 days. 
4.2 Quantitative RT-PCR TaqMan assay 
Total RNA was isolated from confluent monolayers using the RNeasy Mini Kit. Total RNA 
was quantified with a NanoDrop-1000 photometer (Witec, Littau, Switzerland). The purity 
of the RNA preparations was high, as demonstrated by the 260 / 280 nm ratio (range 1.8-
2.2). After DNase I digestion, 1 µg of total RNA was reverse transcribed by SuperScript II 
RT-Kit, according to the manufacturer’s protocol, using random hexamers as primers. 
TaqMan analysis was carried out on a 7900HT Sequence Detection System (Applied 
Biosystems). Polymerase chain reaction (PCR) conditions were 10 min at 95°C followed 
by 40 cycles of 15 s at 95°C and 1 min at 60°C. Each TaqMan reaction contained 10 ng 
of cDNA in a total volume of 10 µl. qPCR Mastermix Plus from Eurogentec (Seraing, 
Belgium) was used. Primers and probes were used at concentrations of 900 and 225 nM, 
respectively. Primers were synthesized by Invitrogen (Basel, Switzerland) and 
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Eurogentec (Seraing, Belgium). For corresponding sequences of primers and probes for 
TaqMan analysis see Table 1. All samples were run in triplicates and not reverse-
transcribed RNA served as a negative control. Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) mRNA expression was measured to compare expression of 
the other genes with the absolute amount of a well-known house-keeping gene. 
Gene Accession No. Sequence 
BCRP AY333756 Forward: 5`-CAGGTCTGTTGGTCAATCTCACA-3` 
Reverse: 5`-TCCATATCGTGGAATGCTGAAG-3` 
Probe:  5`-CCATTGCATCTTGGCTGTCATGGCTT-3` 
MDR1 M14758 Forward: 5`-CTGTATTGTTTGCCACCACGA-3` 
Reverse: 5`-AGGGTGTCAAATTTATGAGGCAGT-3` 
Probe: 5`-AAGCTGTCAAGGAAGCCAATGCCTATGACTT-3` 
MRP1 NM_004996 Forward: 5`-GGGCTGCGGAAAGTCGT-3` 
Reverse: 5`-AGCCCTTGATAGCCACGTG-3` 
Probe: 5`-CCTCCACTTTGTCCATCTCAGCCAAGAG-3` 
MRP2 NM_000392 Forward: 5`-ACTGTTGGCTTTGTTCTGTCCA-3` 
Reverse: 5`-CAACAGCCACAATGTTGGTCTCTA-3` 
Probe: 5`-CTCAATATCACACAAACCCTGAACTGGCTG-3` 
MRP3 AF085690 Forward: 5`-GGTGGATGCCAACCAGAGAA-3` 
Reverse: 5`-GCAGTTCCCCACGAACTCC-3` 
Probe: 5`-CCAACCGGTGGCTGAGCATCG-3` 
MRP4 AF071202 
(Taipalensu) 
Forward: 5`-AAGTGAACAACCTCCAGTTCCAG-3` 
Reverse: 5`-GGCTCTCCAGAGCACCATCT-3` 
Probe:  5`-CAAACCGAAGACTCTGAGAAGGTACGATTCCT-3` 
MRP5 NM_005688 Forward: 5`-CTGCAGTACAGCTTGTTGTTAGTGC-3` 
Reverse: 5`-TCGGTAATTCAATGCCCAAGTC-3` 
Probe:  5`-CTGACGGAAATCGTGCGGTCTTGG-3` 
GAPDH M17851 Forward: 5`-GGTGAAGGTCGGAGTCAACG-3` 
Reverse: 5`-ACCATGTAGTTGAGGTCAATGAAGG-3` 
Probe:  5`-CGCCTGGTCACCAGGGCTGC-3` 
Table 1 Sequences of TaqMan Primers and Probes. 
For absolute quantification, external standard curves were used. Standards were gene-
specific cDNA fragments that cover the TaqMan primer/probe area and they were 
generated by PCR. For sequences of the corresponding primers, see Table 2. The PCR 
products were purified by running a 1.5% agarose gel and a subsequent gel extraction 
(gel extraction kit, Qiagen). The standards were quantified using the PicoGreen reagent 
(Molecular Probes, Eugene, OR, USA) and were checked by sequencing (Microsynth 
GmbH, Balgach, Switzerland).  
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4.3 RT-PCR 
As described in section 4.2 total RNA was isolated from D3 cells and reverse transcribed. 
PCR of the human transferrin receptor (hTfR) was performed with a thermocycler 
(Biometra, Göttingen, Germany). Each sample was amplified for 35 cycles (94°C for 30 
s, 55°C for 30 s, 72°C for 60 s). The reaction mixture contained 2.5 µl of the cDNA 
template, 0.25 U AmpliTaq gold DNA polymerase, 2.5 µl 10x PCR buffer, MgCl2 at a final 
concentration of 3 mM, 2 µl of dNTP reaction mixture (2.5 mM each), 7.5 pmol of each 
primer and water to a final volume of 25 µl. Primers for the hTfR were designed 
according to Milstone et al. (Milstone et al. 2006) and sequences are listed in Table 2. As 
negative control, not reverse transcribed RNA was used. The PCR products were 
separated by gel electrophoresis (1.5% agarose) and visualized by UV light in the 
presence of ethidium bromide. 
Gene Accession No. Sequence 
hTfR NM_003234 Forward:  5’-CTGCTATGGGACTATTGCTGTG-3’ 
Reverse:  5’-CCGACAACTTTCTCTTCAGGTC-3’ 
BCRP AY333756 Forward: 5'-TTTCAGCCGTGGAACTCTTT-3' 
Reverse: 5'-TGAGTCCTGGGCAGAAGTTT-3' 
MDR1 M14758 Forward: 5`-ACAGTCCAGCTGATGCAGAGG-3` 
Reverse: 5`-CCTTATCCAGAGCCACCTGAAC-3` 
MRP1 NM_004996 Forward:  5`-CACACTGAATGGCATCACCTTC-3` 
Reverse:  5`-CCTTCTCGCCAATCTCTGTCC-3` 
MRP2 NM_000392 Forward: 5`-CCAATCTACTCTCACTTCAGCGAGA-3` 
Reverse:  5`-AGATCCAGCTCAGGTCGGTACC-3` 
MRP3 AF085690 Forward: 5`-TCTATGCAGCCACATCACGG-3` 
Reverse: 5`-GTCACCTGCAAGGAGTAGGACAC-3` 
MRP4 AF071202 
(Taipalensu) 
Forward:  5`-AAGTGAACAACCTCCAGTTCCA-3` 
Reverse: 5`-CCGGAGCTTTCAGAATTGAC-3` 
MRP5 NM_005688 Forward:  5`-CTGCAGTACAGCTTGTTGTTAGTGC-3` 
Reverse:  5`-TCGGTAATTCAATGCCCAAGTC-3` 
GAPDH M17851 Forward:  5`-ACATCGCTCAGAACACCTATGG-3` 
Reverse: 5`-GCATGGACTGTGGTCATGAGTC-3` 
Table 2 Sequences RT-PCR primers. 
4.4 Western Blot 
The presence of P-gp and BCRP was studied by Western Blot analysis using the murine 
antibody (mAb) C219 (Alexis) against P-gp and the mAb BXP-21 (Alexis) against BCRP. 
SDS-polyacrylamide gel electrophoresis was performed with a Mini-Protean II apparatus 
(Bio-Rad, Zürich, Switzerland). To hCMEC/D3 cell homogenates (0.7-0.9 mg/ml protein, 
obtained from cells cultivated under standard conditions) the same amount of Lämmli 
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buffer (Bio-Rad) was added. The samples were loaded onto an acrylamide/bisacrylamide 
gel (10% for BCRP, 6.5% for P-gp). After electrophoresis, the proteins were transferred 
electrophoretically (2 h at a constant amperage of 250 mA) to a 0.45 µm pore size 
nitrocellulose membrane using a Mini Transblot cell (Bio-Rad). The transfer buffer 
contained 192 mM glycine, 25 mM Tris–HCl, and 20% methanol. The membrane was 
blocked overnight at 4°C with 5% powdered skimmed milk in PBS containing 0.05% 
Tween 20 (PBS-T). Washed membranes were incubated with mAb C219 (1 µg/ml) or 
mAb BXP-21 (1.25 µg/ml) in PBS-T and 1% powdered skimmed milk for 2 h at 37°C. 
Washed membranes were incubated for 1 h at room temperature with horseradish 
peroxidase-conjugated rabbit anti-mouse IgG (1:500) in PBS-T containing 1% milk 
powder. Membranes were washed in PBS-T and P-gp or BCRP and were visualized 
using enhanced chemiluminescence detection (ECL-kit, Amersham Otelfingen, 
Switzerland). 
4.5 Transport assay 
For transport experiments hCMEC/D3 cells were seeded on type I collagen precoated 
Transwell® filters (polycarbonate 12 well, pore size 3.0 µm or polyester [clear], 12 well, 
pore size 0.4 µm) in a density of 50,000 cells/cm2. Assay medium was changed after 4 
and 7 days and transport assays were performed 7 to 10 days after seeding. Both sides 
of the chamber were washed with prewarmed HBSS supplemented with 10 mM HEPES, 
1mM Na-Pyruvate, pH 7.4 at 37°C (HBSS-P). At time t=0, 0.3 µCi [3H]-inulin, [14C]-
sucrose, [3H]-morphine, [3H]-propranolol, [14C]-midazolam or 20 µM lucifer yellow were 
applied on the apical donor compartment. For propranolol transport, 10 µM of unlabeled 
substance were added.  After 5, 10, 20, 30, 45 and 60 min the filters were moved to a 
new acceptor-well containing 1.5 ml prewarmed HBSS-P and samples were taken from 
the basolateral acceptor compartment of the well from the previous time point. Insta Gel 
plus scintillation liquid was added to the radioactive samples, and analysis was 
performed by scintillation counting (Packard TriCarb2000, Canberra Packard S.A.). 
Detection of lucifer yellow was carried out with a Perkin-Elmer HTS 7000 Bio Assay 
Reader using the following parameters: excitation at 430 nm, emission 535 nm.  
Permeabilities of the test compounds are given as permeability coefficients.  They take 
into account the relation between the permeability of the monolayer and the permeability 
of empty filters (precoated with rat-tail collagen, without cells). The slopes of the volume 
cleared vs. time represent the clearance for each condition. The clearance of each filter 
well is related to the clearance of empty filter wells and was used to calculate the 
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permeability coefficients (Pe) of the endothelial monolayer according to (Cecchelli et al. 
1999): 
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where PS is the permeability-surface area product, A is the surface area of the filter and 
me and mf are the volumes cleared vs. time corresponding to endothelial cells on filters 
and to empty filters, respectively. 
For bidirectional transport experiments, cells were cultured as described above, but with 
5% human serum instead of 2.5% FCS. After washing the cells with HBSS-P 5 µM 
rhodamine 123 (R123) and 0.6 µCi/ml [14C]-sucrose were applied on the apical or 
basolateral compartment. The opposite compartment was filled with HBSS-P. After 10, 
20, 40 and 60 min samples were drawn from the opposite compartment and were 
replaced with the same amount of HBSS-P. Fluorescence detection of R123 was carried 
out on a Perkin-Elmer HTS 7000 Bio Assay Reader using the following settings: 
excitation: 485 nM, emission: 535 nM. [14C]-sucrose was analyzed as described above. 
4.6 Drug accumulation assay 
Drug accumulation assays were performed to test functional activity of P-gp, BCRP and 
MRPs. hCMEC/D3 cells were seeded on rat collagen type I precoated 24-well plates in a 
density of 37,000 cells/well. After 4 and 7 days the medium was changed. All assays 
were performed on a temperature-controlled shaker (THERMOstar, BMG labtech, 
Offenburg, Germany) at 37°C and 120 rpm. All monolayers were washed 3 times with 
prewarmed HBSS-P (37°C) and were preincubated for 15 min with corresponding 
inhibitors dissolved in HBSS-P (100 µM verapamil for P-gp, 50 µM prazosin for BCRP, 10 
µM MK-571 for MRPs). The solutions were removed and the cells were incubated with 
HBSS-P containing the test-compounds (5 µM R123, 0.3 µCi [3H]-digoxin, for P-gp, 0.3 
µCi [3H]-methotrexate for MRPs and 20 µM mitoxantrone for BCRP assay) and 
corresponding inhibitors for 30 min. To reach a final concentration of 5 µM digoxin and 1 
µM methotrexate corresponding unlabeled substance was added to the radioactive 
tracers. After loading the plate was put on ice and the cells were washed twice with ice-
cold HBSS-P with or without the test inhibitors. Subsequently HBSS-P alone and with 
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inhibitors was added to the cells, and the efflux took place for 40 min (mitoxantrone) or 
60 min (all other substrates). The reaction was stopped by putting the plate on ice and 
rinsing 2 times with ice cold HBSS-P. Cells, which were treated with radioactive labeled 
compounds, were detached using trypsin and were transferred to scintillation vials. After 
adding Insta Gel plus, the samples were analyzed in a scintillation counter (Packard 
TriCarb2000). The cells loaded with fluorescent drugs were lysed with 0.8% (v/v) Triton 
X-100 in PBS for 15 min at 37°C. Samples were taken and fluorescence detection was 
carried out on a Perkin-Elmer HTS 7000 Bio Assay Reader using the following settings: 
R123 (excitation: 485 nm, emission: 535 nm), mitoxantrone (excitation: 610 nm, 
emission: 685 nm). 
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5.1 Abstract 
The human brain endothelial capillary cell line hCMEC/D3 has been developed recently 
as a model for the human blood-brain barrier. In this study a further characterization of 
this model was performed with special emphasis on permeability properties and active 
drug transport. Para- or transcellular permeabilities (Pe) of inulin (0.74*10-3 cm/min), 
sucrose (1.60*10-3 cm/min), lucifer yellow (1.33*10-3 cm/min), morphine (5.36*10-3 
cm/min), propranolol (4.49*10-3 cm/min) and midazolam (5.13*10-3 cm/min) were 
measured. By addition of human serum the passive permeability of sucrose could be 
reduced significantly by up to 39%. Furthermore, the expression of a variety of drug 
transporters (ABCB1, ABCG2, ABCC1-5) as well as the human transferrin receptor was 
demonstrated on the mRNA level. ABCB1, ABCG2 and transferrin receptor proteins were 
detected and functional activity of ABCB1, ABCG2 and the ABCC family was quantified 
in efflux experiments. Furthermore, ABCB1-mediated bidirectional transport of rhodamine 
123 was studied. The transport rate from the apical to the basolateral compartment was 
significantly lower than that in the inverse direction, indicating directed P-glycoprotein 
transport. The results of this study emphasize the usefulness of the hCMEC/D3 cell line 
as an in vitro model to study drug transport at the level of the human blood-brain barrier. 
5.2 Introduction 
The ability or inability of a drug to penetrate into the brain is a key consideration in drug 
design. Drugs for treating central nervous system (CNS) disorders need to penetrate the 
blood-brain barrier (BBB). Conversely, non-penetration of the BBB is desired for 
peripherally acting drugs to minimize potential CNS-related side effects. The BBB is 
composed of brain capillary endothelial cells (BCEC). In contrast to other endothelial 
cells, BCEC are characterized by low passage rates for small hydrophilic molecules. This 
low permeability is caused by decreased transcytotic activity and by tight junctions and 
adherens junctions that limit paracellular passage (Wolburg and Lippoldt 2002). 
Furthermore, BCEC protect the brain from entry of potentially harmful endogenous and 
exogenous compounds by expression of non-specific transporter proteins which pump 
small hydrophobic molecules from the brain back into the blood. The first discovered 
export pump at the BBB was ABCB1 (formerly P-glycoprotein, P-gp, MDR1) (Cordon-
Cardo et al. 1989) which is expressed at the apical membrane of BCEC where it limits 
the entry of drugs, toxic compounds and their metabolites into the brain (Schinkel 1999). 
The recently discovered ABCG2 (formerly breast cancer resistance protein, BCRP) was 
found to be expressed at the luminal surface of BCEC where it limits the entry of toxic 
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compounds to the brain (Cooray et al. 2002; Eisenblatter and Galla 2002; Cisternino et 
al. 2004). A further class of drug transporters at the BBB is the family of the MRPs 
(multidrug resistance proteins). MRP1 and MRP3-6 are expressed at the BBB on either 
the apical, basolateral or both sides of the BCECs, whereas the expression of MRP2 at 
the human BBB remains unclear (for review see (Loscher and Potschka 2005)). It should 
be noted that most drug transporting proteins are expressed constitutively in healthy 
brain tissue in line with their protective function. 
The development of a model of the BBB that allows a reliable prediction of drug brain 
penetration in vitro has been a goal for a long time. In the past, efforts were made to 
develop cell culture models that mimic the in vivo situation. Isolated primary BCEC of 
various origins were used as models, sometimes co-cultured with astrocytes (Rowland et 
al. 1991; Huwyler et al. 1996; Cecchelli et al. 1999; Torok et al. 2003). This combination 
mimics the in vivo situation, where BCEC are surrounded by astrocytes and pericytes 
that are crucial for cell maturation and development of the tight junctions (Abbott et al. 
2006). These models exhibited high electrical resistances, low permeabilities to small 
molecular weight compounds and functional expression of the most important drug 
transporters. Since isolation of BCEC is very laborious and time-consuming work, 
different immortalized rat or mouse cell lines, such as RBE4 (Roux et al. 1994), GPNT 
(Regina et al. 1999) and b.End3 (Omidi et al. 2003) have been developed. Drawbacks for 
their use as an in vitro model of the human BBB were their high paracellular 
permeabilities and animal origin. So far only three human immortalized cell lines have 
been developed: BB19 (Prudhomme et al. 1996; Kusch-Poddar et al. 2005), the recently 
described NKIM-6 (Ketabi-Kiyanvash et al. 2007) and the hCMEC/D3 (Weksler et al. 
2005) cell line which was investigated in this study. Whereas the use of the BB19 cell line 
is limited by its high sucrose permeability, no permeability data for NKIM-6 are available. 
So far, active bidirectional transport has not been demonstrated in any human BBB cell 
line.  
Recently, the hCMEC/D3 cell line has been developed by immortalization of primary 
human BCEC through co-expression of hTERT and the SV40 large T antigen via a 
lentiviral vector system. The hCMEC/D3 cells express typical endothelial markers such 
as CD31, VE-cadherin, and von Willebrand factor. Cells show a stable normal karyotype, 
maintain contact-inhibited monolayers in culture and form capillary tubes in matrix. 
Furthermore, this cell line expresses chemokine receptors and up-regulates adhesion 
molecules in response to inflammatory cytokines. Finally, cells demonstrate BBB 
characteristics such as the formation of tight junction proteins and the capacity to exclude 
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drugs. In culture, these cells functionally express important active transport proteins such 
as ABCB1, ABCC1 and ABCG2 (Weksler et al. 2005). 
A recent study examined the hCMEC/D3 cell in a humanized dynamic in vitro BBB model 
under flow. In comparison to primary human brain microvascular endothelial cells in co-
culture with human astrocytes, hCMEC/D3 cells exerted the same high transendothelial 
electrical resistance (TEER) even in absence of astrocytes (Cucullo et al. 2008). Other 
studies used the hCMEC/D3 as a model for studying BBB signaling and interaction with 
immune cells or pathogens (Levoye et al. 2006; Mairey et al. 2006; Viegas et al. 2006; 
Forster et al. 2008). Since there is a need for further evaluation of permeability 
properties, this study was performed.  
The aim of the present study was to expand the evaluation of the hCMEC/D3 cell line as 
a predictive in vitro model of the BBB. Features which are important to predict the 
passage of molecules through the BBB are: a high tightness to hydrophilic low molecular 
weight compounds, a good permeability for hydrophobic low molecular weight 
compounds, and expression and function of transport proteins. Therefore we examined 
para- and transcellular transport rates of a series of compounds with different 
physicochemical properties and molecular weights in order to evaluate tightness and 
discrimination between high and low transport rates. In a further step it was our goal to 
further decrease paracellular permeability. The effect of human serum on sucrose 
permeability was investigated. To evaluate the transporter expression of our model we 
measured mRNA levels of P-gp, BCRP and MRP1-5 as well protein expression of P-gp 
and BCRP. We also measured the expression of the human transferrin receptor (hTfR) in 
the hCMEC/D3 cells. Functional activity of P-gp, BCRP and the MRP family in 
hCMEC/D3 cells, was tested by uptake assays using specific substrates and inhibitors. 
Furthermore, bidirectional transport of rhodamine 123 (R123), a P-gp substrate, was 
measured. 
5.3 Materials and Methods 
5.3.1 Materials 
Ko-143, [14C]-midazolam and TaqMan Mastermix were kindly provided by Roche 
Pharmaceuticals (Basel, Switzerland). All culture plasticware and Transwell® filters were 
purchased from Corning (Baar, Switzerland). Cell culture medium EBM-2 and 
supplements (vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF-
1), epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), fetal calf serum 
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(FCS) and hydrocortisone) were obtained from Lonza Bioscience (Verviers, Belgium). 
[3H]-morphine, [14C]-sucrose and [3H]-digoxin were from Perkin Elmer (Schwerzenbach, 
Switzerland), [3H]-inulin, [3H]-propranolol, were from Amersham (Otelfingen, Switzerland) 
and [3H]-methotrexate was purchased from Moravek (Brea, CA, USA). Hydrocortisone, 
lucifer yellow, mitoxantrone and verapamil, were purchased from Sigma (Buchs, 
Switzerland). Alexa 488 labeled secondary antibody, basic FGF, DNase I, Hank’s 
balanced salt solution (HBSS), HEPES, penicillin-streptomycin, sodium pyruvate and 
SuperScript II RT-Kit were purchased from Invitrogen (Basel, Switzerland). Rat-tail 
collagen type I was obtained from Becton Dickinson (Allschwil, Switzerland). RNeasy 
Mini Kit was purchased from Qiagen (Hilden, Germany). qPCR Mastermix Plus was 
purchased from Eurogentec (Seraing, Belgium). Random hexamers and AmpliTaq gold 
DNA polymerase were obtained from Applied Biosystems (Rotkreuz, Switzerland). 
dNTPs were purchased from BioRad (Reinach, Switzerland). The murine antibody (mAb) 
C219 against P-gp and the mAb BXP-21 against BCR were purchased from Alexis. 
Rabbit anti-mouse IgG was purchased from Dako (Baar, Switzerland). Insta Gel plus 
scintillation liquid was obtained from Perkin-Elmer. All other chemicals were purchased 
from commercial sources at the highest quality available. Human AB serum (HS) was 
obtained from the blood donor bank (Blutspendezentrum, Universitätsspital Basel, 
Switzerland). A pool of 6 blood samples from healthy individuals with blood group AB 
was sterile filtered and heat inactivated for 1 h at 65°C. 
5.3.2 Cell culture 
For description see section 4.1. 
5.3.3 Quantitative RT-PCR TaqMan assay 
For description see section 4.2. 
5.3.4 RT-PCR 
For description see section 4.3. 
5.3.5 Western blot 
For description see section 4.4. 
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5.3.6 Flow cytometry analysis (FACS) 
Cell suspensions of hCMC/D3 cells were prepared from confluent cell monolayers 
dispersed mechanically. The cells (0.5 x 106 cells in assay buffer: 0.17 M NaCl, 3.3 mM 
KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4) were incubated with 20 µg/ml of OX26 
for 20 min at 4°C in the presence of 10% FCS. Control experiments (negative controls in 
absence of OX26 or secondary antibody only) were done in parallel. Cells were washed 
with ice-cold assay buffer. Cells were incubated with secondary antibody for 20 min at 
4°C in 10% fetal calf serum in assay buffer using a 1:400 dilution of goat anti-mouse 
Alexa 488 labeled secondary antibody. Cells were washed twice with ice-cold assay 
buffer and were analyzed using a FACScan flow cytometer (Beckton Dickinson, Franklin 
Lakes, NJ, USA). Raw data were evaluated using Cytomation Summit software 
(Cytomation, Fort Collins, CO, USA). 
5.3.7 Transport assay 
For description see section 4.5. 
5.3.8 Drug accumulation assay 
For description see section 4.6. 
5.3.9 Statistics 
For statistical comparison, data from the treatment groups were compared with those 
from the controls by analysis of variance (ANOVA) with subsequent Dunnett’s multiple 
comparison test. Where groups were compared, a pair-wise two-sided unpaired t-test 
was used. All comparisons were performed using SPSS for Windows software (version 
14.0, SPSS Inc. Chicago, IL, USA). 
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5.4 Results  
5.4.1 Transport assays 
 
Figure 4 Permeability coefficients (Pe values *10-3 cm/min) of model compounds with different 
molecular weight and hydrophilicity. Data represent means of n=6 ± SEM. 
The BBB exhibits a very high tightness to hydrophilic compounds in vivo whereas 
lipophilic drugs can easily permeate the barrier. To assess the in vitro permeability of the 
hCMEC/D3 cell monolayer, a variety of test compounds with different physiochemical 
properties were investigated: inulin, lucifer yellow, sucrose, propranolol, morphine and 
midazolam. As shown in Figure 4, the lowest Pe value was measured for the large 
hydrophilic compound inulin (0.74*10-3 cm/min). This value was comparable to the result 
of Weksler et al. where a Pe of 0.37*10-3 cm/min was measured. For the much smaller 
hydrophilic molecules sucrose (1.60*10-3 cm/min) and lucifer yellow (1.33*10-3 cm/min), 
higher permeabilities were measured, which are in agreement with previous data 
(Weksler et al. 2005). The highly lipophilic compounds midazolam (5.13*10-3 cm/min) and 
propranolol (4.49*10-3 cm/min), which were investigated for the first time in this cell line, 
had a 7-fold higher permeability compared to inulin. Morphine (5.36*10-3 cm/min) also 
had 7-fold higher permeability compared to inulin (Figure 4). All transport experiments 
were performed 8-10 days after seeding of the cells. This was found to be the time frame 
where the monolayer had the lowest permeability with respect to apparent permeabilty of 
extracellular markers.  
The hCMEC/D3 cell line for transport studies 
 
27 
5.4.2 Influence of human serum on the sucrose permeability 
 
Figure 5 Effect of human serum on the [14C]-sucrose permeability coefficients (Pe values *10-3 
cm/min) of hCMEC/D3 monolayers. Data represent means of n=6 ± SEM (*: p<0.05). 
As is known from literature, the tightness of the BBB depends on the correct assembly of 
the tight junctions. In vivo the formation of tight junctions is influenced by soluble factors 
of surrounding astrocytes and pericytes as well as by blood-derived compounds. It is the 
aim of an in vitro system to mimic the in vivo situation as closely as possible. Since the 
hCMEC/D3 cells are derived from human tissue, we replaced the FCS contained in the 
medium with HS, when the cells were growing on filters, in order to mimic the in vivo 
situation. Exposure of hCMEC/D3 cells to 2.5-10% HS resulted in a significant decrease 
of [14C]-sucrose permeability (Figure 5). Pe values of [14C]-sucrose were reduced by 32% 
(2.5% HS), 34% (5% HS) and 39% (10% HS) compared to control cells, grown under 
standard conditions (2.5% FCS) as shown in Figure 5. 
5.4.3 ABC-transporter expression 
The expression of MDR1, BCRP, MRP1, MRP2, MRP3, MRP4 and MRP5 in hCMEC/D3 
cells was measured at the mRNA level by quantitative RT-PCR (Figure 6). The 
transcripts per µg RNA of MDR1, BCRP, and MRP1-5 range from 2*104 for MRP2 to 
7*108 for MRP4. mRNA expression of BCRP, MDR1 and MRP1 lies in a similar range 
between 0.44–1.26*106 transcripts per µg RNA. The expression of MRP2 is very low, 
compared to the other transport proteins.  
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Figure 6 Absolute quantitative mRNA expression of ABC-transporters and GAPDH in hCMEC/D3 
cells given as log(transcripts / µg RNA). Data represent means of n=6 ± SEM. 
The expression of P-gp and BCRP proteins was assessed by Western Blot analysis 
using the C219 antibody against P-gp and the BXP-21 antibody against BCRP (Figure 
7). P-gp with a molecular weight of 170 kDa was detected in hCMEC/D3 cell line (lane A) 
and in the human colon carcinoma cell line CACO-2 (lane B). CACO-2 cells are known to 
express the human P-gp at the protein level (Maier et al. 2007). Expression of BCRP with 
a molecular weight of 70 kDa was shown in the hCMEC/D3 cell line (lane C), and in a 
protein sample isolated from the human BBB cell line BB19 (lane D). The BB19 cell line 
was shown to express BCRP on protein level (Kusch-Poddar et al. 2005). BCRP as well 
as P-gp proteins were detected in the hCMEC/D3 cell line as shown in Figure 7, with 
expected molecular weights of 70 kDa and 170 kDa respectively.  
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Figure 7 Western Blot analysis of P-gp (170kDa) and BCRP (70kDa) in hCMEC/D3 cells (D3). 
Bands represent protein of: hCMECD/3 cells (A and C), CACO-2 cells (B) and BB19 cells (D). 
5.4.4 Expression of the transferrin receptor 
The expression of hTfR was investigated using RT-PCR. The amplified 180 kb cDNA 
PCR product was detected in independent samples of hCMEC/D3 cells (data not shown), 
demonstrating the expression of the hTfR at the mRNA level.  
 
Figure 8 Transferrin receptor expression in hCMEC/D3: Immunolabeling and flow cytometry 
analysis using the anti-transferrin mAb OX26 (black: negative control; grey: second antibody only; 
white: OX26 immunostaining). 
To detect the hTfR at the protein level flow-cytometry analysis was performed using the 
OX26 mAb against the hTfR. Huwyler et al. have described the OX26 mAb extensively 
(Huwyler et al. 1999). The data shown in Figure 8 clearly show that the hCMEC/D3 cell 
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line expresses the hTfR at the protein level, which is essential for the endocytotic uptake 
of iron-loaded transferrin into the brain.  
5.4.5 Efflux assays 
Transporter Substrate Inhibitor 
% change 
compared to 
control SEM p-value 
P-gp R123 verapamil + 179.35 7.77 < 0.001 
P-gp R123 Ko-143 - 17.19 4.71 = 0.38 
P-gp digoxin verapamil + 41.5 14.00 < 0.05 
MRP methotrexate MK-571 + 85.33 5.84 < 0.005 
BCRP mitoxantrone prazosin + 50.37 21.21 > 0.15 
BCRP mitoxantrone β-estradiol + 83.08 38.03 < 0.005 
BCRP mitoxantrone Ko-143 + 87.83 19.41 < 0.005 
BCRP mitoxantrone verapamil + 101.77 25.48 < 0.001 
Table 3 Effects of ABC-transporter inhibitors on the remaining substance in hCMEC/D3 cells after 
a defined efflux time. Data are given as percent change of intracellular remaining amount of the 
indicated substrate in the presence of an inhibitor compared to the amount in untreated control 
cells. Intracellular content of R123 (5 µM), digoxin (5 µM) and methotrexate (1 µM) was measured 
after 60 min, content of mitoxantrone (20 µM) after 40 min. Efflux was performed in the presence 
of the specific inhibitors verapamil (100 µM), Ko-143 (1 µM), MK571 (10 µM), prazosin (50 µM) 
and β-estradiol (20 µM). Two or more independent experiments were performed. Data are means 
of a representative experiment (n=3 ± SEM). 
As shown in Table 3, the remaining amount of R123 and digoxin in the hCMEC/D3 cells 
was measured to investigate the functional expression of P-gp. The presence of the P-gp 
inhibitor verapamil increased the remaining amount of both compounds significantly, 
indicating that the drug export was decreased in the presence of the P-gp inhibitor. 
Verapamil increased R123 accumulation compared to its control by 179% whereas the 
accumulation of digoxin was increased by 41% in the presence of verapamil. The BCRP 
inhibitor Ko-143 did not influence the efflux of R123 significantly. In the presence of the 
MRP inhibitor MK571 an increase by 85% of the remaining MRP substrate methotrexate 
was observed. 
BCRP function was investigated with mitoxantrone, a shared substrate of BCRP and P-
gp.  The mitoxantrone accumulation after 40 min was measured with and without 
prazosin (a BCRP and P-gp inhibitor), verapamil (a P-gp inhibitor), β-estradiol and Ko-
143 (both specific BCRP inhibitors). The remaining substance was increased by 50%-
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101% compared to control under addition of one of the listed inhibitors. Except for 
prazosin, the remaining mitoxantrone increase was highly significant in the presence of 
the inhibitors. 
5.4.6 Bidirectional transport of the P-gp substrate R123 
Bidirectional transport of the P-gp substrate R123 through hCMEC/D3 monolayers grown 
in standard medium containing 5% HS instead of FCS was measured. In Table 4 the 
permeabilities of sucrose and R123 through empty filters and hCMEC/D3 cells grown on 
filters are given. The permeabilities are given as slope of volume cleared (ml/min) as 
described in the section 4.5. The slopes (ml/min) of the empty filters for both compounds 
in both transport directions were at least twice as high as the slopes for the cells grown 
on filters.  
 
Figure 9 Bidirectional transport of R123 (solid lines) and sucrose (dashed lines) through 
hCMEC/D3 monolayers. Black squares and triangles indicate transport from apical to basolateral 
compartment. Black circles and down-pointing triangles indicate transport from basolateral to 
apical compartment. Data represent means of n=6 ± SEM (**: p<0.005, ***: p<0.0005). 
As shown in Figure 9, R123 was transported to a significantly higher amount from 
basolateral (B) to apical (A) than from A to B. After 60 min the ratio of R123 transport A 
to B divided by B to A was 0.56. This difference was highly significant. [14C]-sucrose was 
used as extracellular tightness marker. A higher transport from B to A compared to A to B 
was also observed for sucrose. However, the ratio of 0.79 was clearly higher than that 
observed for R123, indicating that R123 transport was restricted by P-gp. These findings 
demonstrate active bidirectional transport of the P-gp substrate R123 in hCMEC/D3 cells. 
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Compound sucrose R123 
Direction of 
Transport A → B B →  A A →  B B →  A 
 cells filter cells filter cells filter cells filter 
m (ml/min) 0.52 1.08 0.65 2.05 0.56 1.69 1.07 3.04 
Table 4 Permeabilities of R123 and sucrose from apical (A) to basolateral (B) and from 
basolateral to apical. Permeabilities are given as slopes (m) for hCMEC/D3 cells growing on filters 
(cells) and for empty filters (filters). 
5.5 Discussion 
The ability or inability of a drug to penetrate into the brain is a key consideration in drug 
design. Drugs for treating central nervous system (CNS) disorders need to be able to 
penetrate the BBB. BBB non-penetration is desired for peripherally acting drugs to 
minimize potential CNS-related side effects. 
The aim of this study was to enlarge the characterization of the hCMEC/D3 cell line with 
regard to permeability against small molecular weight compounds and macromolecules, 
as well as transporter expression and functionality. Furthermore, directed P-gp transport 
was studied.  
Since tightness to hydrophilic compounds is a main aspect of a good BBB, we 
investigated the passive paracellular permeabilities of sucrose, lucifer yellow and inulin 
as paracellular markers. Our sucrose (1.60*10-3 cm/min) and inulin (0.74*10-3) data are in 
concordance with the data generated by Weksler et al. (Weksler et al. 2005). In 
comparison with rat cell lines, such as RBE4 (4.8*10-3 cm/min) (Rist et al. 1997), GPNT 
(7.4*10-3 cm/min) (Regina et al. 1999) the hCMEC/D3 cell line exhibits a higher 
paracellular resistance. For the bovine co-culture model using primary BCEC and 
primary astrocytes, lower Pe values have been measured (0.75*10-3 cm/min) (Cecchelli et 
al. 1999). A model using primary human BCEC and astrocytes in co-culture showed Pe 
values for sucrose (1.0*10-3 cm/min) in a similar range compared to our results (Megard 
et al. 2002). The Pe of inulin in hCMEC/D3 cells was close to the reported values in the 
primary BCEC co-culture model (0.37*10-3 cm/min) (Cecchelli et al. 1999). 
Transcellular transport was investigated using the lipophilic low molecular weight 
compounds propranolol, morphine and midazolam. These molecules crossed the 
hCMEC/D3 monolayers to a much higher extent than the hydrophilic molecules. The ratio 
between propranolol and inulin permeabilities was 6.1, whereas the ratio between 
propranolol and sucrose was 2.8. This ratio allows discrimination between molecules with 
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a high or low permeation rate. Compared to a model using porcine BCEC, where the 
ratio between propranolol and sucrose was 5.7, the ratio in our model was lower. 
However, the rat cell line b.End3, which was investigated in the same study, was not able 
to dicriminate between different permeability marker compounds (Omidi et al. 2003).  
As described above the sucrose permeability in the hCMEC/D3 cell line was good but 
still higher compared to the primary co-culture model of Cechelli et al. (Cecchelli et al. 
1999). It is well-known that the maturation and tightness of BCECs can be modulated by 
different astrocyte or blood-derived factors. As the hCMEC/D3 cells are of human origin 
we investigated the effect of HS on hCMEC/D3 monolayers. Incubations of the 
hCMEC/D3 monolayers with different concentrations of HS (2.5, 5, 10%), replacing FCS, 
resulted in a decrease of sucrose permeability, which ranged between 32% and 39%. 
Already at a concentration of 2.5% the sucrose permeability was lower compared to cells 
treated with 2.5% FCS. At the highest concentration of 10% HS a Pe value of 0.97*10-3 
cm/min was measured. This Pe value comes close to the sucrose permeability reported 
for the primary bovine co-culture model by Cecchelli et al., which is considered as a gold 
standard (Cecchelli et al. 1999). This finding is in contrast to other studies. In presence of 
ox serum decreased paracellular tightness was observed in primary porcine models of 
the BBB (Hoheisel et al. 1998; Nitz et al. 2003). However, endothelial cells of different 
origins and other types of serum compared to our experiments were used. The 
mechanism by which HS increases the tightness is unclear. Further studies are needed 
to clarify the involved processes.  
Beside a morphology, which is similar to the in vivo situation and a good tightness 
mediated by tight junctions, the expression and functionality of ABC-transporters is a key 
feature of a good in vitro model. In addition to Weksler et al. (Weksler et al. 2005) who 
investigated mainly MDR1, MRP1, MRP5 and BCRP, we also tested MRP2, MRP3 and 
MRP4 expression at the mRNA level. The rank order of ABC-transporter mRNA 
expression in hCMEC/D3 cells was MRP4 > MRP5 > MDR1 > BCRP > MRP1 > MRP3 > 
MRP2, whereas the MRP2 expression level was around 100 fold lower compared to the 
other transporters. Similar results were obtained independently with the same cell line by 
other investigators (S Dauchy, X Declèves, JM Scherrmann, personal communication).  
It is important to know that the expression of different ABC-transporters is highly variable 
among different species. Furthermore, differences are observed between brain tissue 
preparations, primary cultures of BCECs and cell lines: In a model of isolated primary rat 
BCECs a high expression of Mdr1a, Mrp1, Mrp4 and Bcrp mRNA was observed (Hori et 
al. 2004; Ohtsuki et al. 2007) as summarized in Table 5. These findings were supported 
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by Enerson and Drewes showing high expression of Bcrp, Mdr1 and Mrp5 in freshly 
isolated rat brain microvessels (Enerson and Drewes 2006). Higher expression levels of 
MRP1, MRP4, MRP5 and MRP6 were found in isolated primary BCEC from bovine origin 
(Zhang et al. 2000).  
Ranking of ABC-
transporter expression 
Expression 
level Tissue Species Reference 
MRP4 > MRP5 > MDR1 > 
BCRP > MRP1 > MRP3 > 
MRP2 
mRNA (qRT-
PCR) 
hCMEC/D3 cell 
line 
human this publication 
Mdr1a > Mrp1 > Mrp4 > Bcrp 
>> Mrp5 > Mrp3 >> MRP6 > 
Mrp2 
mRNA (qRT-
PCR) 
primary BCECs rat (Hori et al. 2004; 
Ohtsuki et al. 
2007) 
Bcrp > Mdr1 > Mrp5 > Mrp1 = 
Mrp3 = Mrp4 =  Mrp6 
mRNA (qRT-
PCR) 
freshly isolated 
brain 
microvessels 
rat (Enerson and 
Drewes 2006) 
MRP4 = MRP5 = MRP6 > 
MRP1 > MRP3; MRP2 (nd) 
mRNA (RT-
PCR) 
primary BCEC bovine (Zhang et al. 
2000) 
MRP1 >> MDR1 = MDR3 > 
MRP2 = MRP3 = MRP5 
mRNA (qRT-
PCR) 
isolated primary 
BCECs 
human 
(aneurysmic 
patients) 
(Dombrowski et 
al. 2001) 
MRP1 >> MDR1 > MRP2 > 
MDR3 = MRP5 = MRP3 
mRNA (qRT-
PCR) 
isolated primary 
BCECs 
human 
(epileptogenic 
tissue) 
(Dombrowski et 
al. 2001) 
MRP1, MRP4, MRP5 (nq); 
MRP2, MRP3, MRP6 (nd) 
protein 
(immuno-
fluorescene) 
tissue sections human (Nies et al. 
2004)} 
MRP1 >> BCRP > MRP2 > 
MDR1 
mRNA (qRT-
PCR) 
NKIM-6 cell line human  (Ketabi-
Kiyanvash et al. 
2007) 
Table 5 Ranking of ABC-transporter expression in cells or tissues of different origins (nd: not 
detectable, nq: not quantifiable). 
Human BCECs of different origins (primary cultures) were compared previously (Table 
5). Main differences can be summarized as follows: 1. there are qualitative differences 
with respect to ABC-transporter mRNA expression between cells from tissue obtained 
from aneurysm operations and epileptogenic tissue. In the epileptogenic tissue, MDR1, 
MRP2 and MRP5 were significantly increased (Dombrowski et al. 2001). Furthermore, 
the up-regulation of MDR1, MRP1 and MRP2 in epileptogenic tissue was confirmed on 
protein level (Sisodiya et al. 1999; Sisodiya et al. 2001; Aronica et al. 2005). Aronica et 
al. observed that BCRP expression was not significantly altered in epileptogenic tissue 
(Aronica et al. 2005). 2. in contrast to these primary cells, the hCMEC/D3 cells show a 
predominant expression of MRP4 and MRP5 and a reduced expression of MRP1. This is 
in agreement with data from Nies et al. investigating the expression of MRPs in human 
brain tissue. MRP1, MRP4 and MRP5 were found by immunostaining of human brain 
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tissue slices. MRP2, MRP3 and MRP6 were not expressed at detectable levels (Nies et 
al. 2004). Similar data were found in cells from rat and bovine origins (Nies et al. 2004). 
Recently, mRNA expression levels of a selection of different ABC-transporters were 
measured in the human BBB cell line NKIM-6 (Ketabi-Kiyanvash et al. 2007). The rank 
order of transporter expression was MRP1 >> BCRP > MRP2 > MDR1 (Table 5), which 
was different from primary cells of human origin. In particular, this cell line showed an 
extraordinarily high expression of MRP2 compared with MDR1. This is in contrast to our 
findings in the hCMEC/D3 cell line. 
In addition to the transporter expression we also detected the hTfR at mRNA and protein 
level using RT-PCR and flow cytometry analysis. The transferrin receptor is known to be 
expressed at the human BBB, where it is involved in the endo- and transcytosis of the 
iron transport protein transferrin (Pardridge et al. 1987). The expression of the hTfR is 
the basis for endocytosis of transferrin in the hCMEC/D3 cells. In order to validate this 
process further investigations are required.  
Besides mRNA expression of the ABC-transporters it is important to determine their 
expression at the protein level and to investigate whether they are functionally active. At 
the protein level P-gp and BCRP could be detected by Western blotting. For functional 
activity the efflux transporters P-gp, BCRP and members of the MRP family were 
examined by using different substrates and inhibitors. P-gp activity could be shown in 
uptake experiments using the known P-gp substrates R123 and digoxin (Schinkel et al. 
1995). The efflux of these substrates could be inhibited with the P-gp inhibitor verapamil. 
Ko-143 a specific BCRP inhibitor had no influence on R123 efflux, indicating that only P-
gp was responsible for the observed effect. Methotrexate efflux could be inhibited with 
the specific MRP inhibitor MK-571, indicating that members of the MRP family are 
functionally active (Gekeler et al. 1995; Zeng et al. 2001). It is difficult to investigate 
which specific MRP mediates this effect since there is a lack of MRP subtype specific 
inhibitors. In addition, we demonstrated that BCRP is expressed and functionally active in 
hCMEC/D3 cells. This was shown with mitoxantrone, a shared substrate of P-gp and 
BCRP. Mitoxantrone efflux could be inhibited with Ko-143, β-estradiol, which are two 
specific BCRP inhibitors, and verapamil (Allen et al. 2002; Pavek et al. 2005). 
In a next step directed bidirectional P-gp transport was examined. Cells were cultured 
under the improved culture conditions with medium containing 5% HS replacing FCS as 
described before. We investigated the bidirectional transport of R123, a known P-gp 
substrate through hCMEC/D3 monolayers. The lower ratio of R123 flux from apical to 
basolateral compared to sucrose indicates active P-gp mediated transport. The effect 
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was moderate but corresponds to the observed data of R123 efflux experiments. It is 
also in line with the results of bidirectional transport data of vincristine in a bovine primary 
co-culture BBB model (Cecchelli et al. 1999) and digoxin in the murine b.End3 cell line 
(Omidi et al. 2003). In both models active P-gp transport was shown by a 2-fold lower 
transport rate from apical to basolateral than from basolateral to apical. It should be 
noted that the observed asymmetry in bidirectional transport is moderate. In contrast to 
P-pg overexpressing cells, the functional expression level of P-gp in hCMEC/D3 cells 
seems to be low. As a consequence, the ratio between apical to basolateral and 
basolateral to apical transport was in the range of 0.79 for R123. This is 50-fold lower 
compared to a study using P-gp over-expressing MDCK cells for the same substrate 
(Tang et al. 2004). In view of this situation, it is difficult to identify P-gp substrates reliably 
under the conditions used in the bidirectional transport assay of the present work. In 
particular, we could not observe statistically significant differences in Papp in presence or 
absence of P-gp inhibitors such as verapamil. 
Up to now the hCMEC/D3 is the best characterized human BBB cell line. Many 
characteristics that are crucial for a good BBB model, such as specific BCEC markers 
and the expression of the most important junctional proteins have been proven. The 
tightness of the monolayer for hydrophilic high molecular weight compounds is high, and 
hydrophobic compounds are able to cross the artificial barrier by the transcellular way. 
The addition of HS significantly reduced the sucrose permeability. This improvement 
resulted in permeability values close to a primary bovine co-culture BBB model. 
Furthermore, many of the drug transporters, which are found in the human BBB in vivo, 
could be detected in this cell line. It could be shown that most of the drug transporters of 
the ABCB, ABCC and ABCG families and the hTfR are expressed.  MDR1, BCRP and 
MRP1 are functionally active and could be inhibited by specific inhibitors. Moreover, it is 
the first time that active P-gp mediated bidirectional transport was shown in a human 
BBB cell line. This finding allows us to use the hCMEC/D3 cell line as a human BBB 
model to study passive and active transport processes. 
We conclude therefore, that the hCMEC/D3 cell line is the most promising immortalized 
human BBB cell line available today. The model exhibits most of the characteristics that 
are essential for a good predictive BBB in vitro model.  
The hCMEC/D3 cell line for transport studies 
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6.1 Abstract 
The blood-brain barrier is a selective permeability barrier between the blood and the 
central nervous system. Brain endothelial cells form a tight monolayer sealed by tight 
junctions that prevent hydrophilic compounds from passive diffusion into the brain tissue. 
Therefore, a high paracellular resistance is a crucial characteristic for every in vitro model 
of the blood-brain barrier. Such a model is the human brain capillary endothelial cell line 
hCMEC/D3. It shows a low permeability against small hydrophilic compounds, yet higher 
than in models using primary brain capillary endothelial cells. Since the formation of tight 
junctions is depending on the surrounding milieu it was our aim to improve the tightness 
of hCMEC/D3 monolayers by medium supplements. The paracellular permeabilty was 
assessed by transport of the tightness marker sucrose through hCEMC/D3 monolayers. 
Based on literature reports the effect of N-acetylcysteine, atorvastatin, simvstatin, sodium 
nitroprusside, insulin, transforming growth factor, epidermal growth factor glial cell 
derived growth factor, interferon-β1b, minocycline, heparin, 8-Br-cyclic guanosine 
monophosphate, selenous acid, diclofenac, indomethacin and thalidomide on the 
sucrose permeability in hCMEC/D3 cells. N-acetylcysteine, atorvastatin and sodium 
nitroprusside reduced the sucrose permeability significantly. Additionally, the effect of the 
three compounds on the generation of reactive oxygen species and the expression of the 
junctional protein ZO-1 was determined. N-acetylcysteine and sodium nitroprusside 
significantly reduced the intracellular reactive oxygen species levels whereas atorvastatin 
had no effect. The ZO-1 levels detected by immunocytochemistry were slightly increased 
after treatment with any of the three compounds. However the expression was increased 
at the cell borders as well as within the cytosol. 
Our study revealed evidence that the tightness of hCMEC/D3 monolayer can be 
increased by addition of N-acetylcysteine, atorvastatin and sodium nitroprusside to the 
culture medium. Furthermore the results suggest a potential connection between 
intracellular reactive oxygen species levels and the tightness of the monolayer. 
6.2 Introduction 
The blood-brain barrier is (BBB) is the permeability barrier between the blood and the 
central nervous system. Thereby, it prevents a broad range of compounds from the entry 
to the brain tissue. Tight junctions (TJ) seal the monolayer of endothelial brain capillary 
cells (BCEC) against the passage of small hydrophilic compounds. Therefore, an 
important characteristic of an in vitro model of the BBB is a high paracellular resistance.   
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Recently, the hCMEC/D3 cell line was developed as an in vitro model of the human BBB, 
by immortalizing primary human BCEC. This cell line shows important BBB 
characteristics such as the expression of tight junctional molecules, chemokine receptors 
and active drug efflux transporters (Weksler et al. 2005). Furthermore, in contrast to 
other cell lines the hCMEC/D3 cells form tight monolayers exerting high paracellular 
resistance (Poller et al. 2008). However, the permeability of paracellular marker 
compounds such as sucrose is lower in some in vitro models using primary cultures of 
BCEC of different origins (Cecchelli et al. 1999; Megard et al. 2002). 
From literature, it is known that the molecular composition of TJ can be modulated by 
different factors resulting in an increased or reduced paracellular tightness of the BBB 
(Abbott et al. 2006). The BCEC are in close contact with glial cells namely pericytes or 
astrocytes. These cells release cell growth factors such as epidermal growth factor 
(EGF), transforming growth factor-β1 (TGF-β1) and glial-cell derived neurotrophic factor 
(GDNF), which were shown to increase the paracellular resistance of primary BCEC in 
vitro (Igarashi et al. 1999; Dohgu et al. 2005). It is also known that soluble inflammatory 
mediators such as tumor necrosis factor-alpha (TNF-α) cause a breakdown of the BBB 
barrier properties, which can be prevented by anti-inflammatory drugs (Candelario-Jalil et 
al. 2007). Interferon-beta 1b (IFN-β1b), used in the therapy of multiple sclerosis patients, 
is a drug that prevents the disruption of the BBB in vitro and in vivo possibly be reducing 
the release of pro-inflammatory cytokines and matrix metalloproteinases (MMP) (Kraus 
et al. 2004; Kraus and Oschmann 2006). The MMPs, mainly MMP-7 and MMP-9 are 
involved in the acute breakdown of the BBB during relapses of multiple sclerosis, by 
degrading collagen of the basal lamina (Yang et al. 2005). Furthermore, MMPs can 
cleave IFN-β1b, which can be inhibited by minocycline a potent inhibitor of the MMP-9 
(Brundula et al. 2002; Nelissen et al. 2003). 
Selenous acid and heparin are substances used in the culture medium of in vitro BBB 
models that report low paracellular permeabilities (Franke et al. 1999; Gaillard et al. 
2001; Megard et al. 2002). However, no reports exist that indicate the importance of 
these supplements in order to reach low permeabilities. A recent study reported that 
reactive oxygen species (ROS) disrupt the BBB. This was shown in the GP8 and the 
hCMEC/D3 cell line (Schreibelt et al. 2007). Therefore, we invested four compounds that 
are described to reduce the generation of ROS, namely sodium nitroprusside (SNP), 
atorvastatin, simvastatin and N-acetylcystein (NAC). In vitro NO radical (NO(*)) releasing 
compounds decrease the permeability of isolated primary porcine BCEC monolayers 
(Winter et al. 2008). SNP being also a member of the NO(*) was shown to improve the 
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tightness of primary human BCEC monolayers (Wong et al. 2004). Statins also exert 
BBB stabilizing effects, which was shown for lovastatin, simvastatin and fluvastatin in 
monolyers of BCEC in vitro (Ifergan et al. 2006; Kuhlmann et al. 2006). 
NAC is an antioxidant drug and acts as a radical scavenger, protecting cells against 
oxidative damage of OH radicals and H2O2. It is also a precursor of cysteine which is 
essential for the glutathione (GSH) sythesis. GSH maintains the cellular redox status in 
endothelial cells and protects the cells against ROS (Townsend et al. 2003; Atkuri et al. 
2007).  
The aim of the present study was to investigate the effect of different medium 
supplements on the paracellular tightness in the hCMEC/D3 cell line. Therefore, 
hCMEC/d3 cells were incubated with NAC, the statins atorvastatin and simvstatin, SNP, 
insulin, the growth factors TGF-β1, EGF and GDNF, INF-β1b, minocycline, heparin, 8-Br-
cyclic guanosine monophosphate (8-Br-cGMP), selenous acid and with the anti-
inflammatory drugs dicofenac, indomethacin and thalidomide. After the incubation period 
transport of sucrose through monolayers of hCMEC/D3 cell was measured to determine 
the effect of the supplements on the paracellular permeability. Since the integrity of TJ 
can be disturbed by ROS, their generation in the hCMEC/D3 cells was measured under 
influence of NAC, atorvastatin and SNP. Furthermore, immunolabelling of ZO-1 was 
performed after treatment with NAC, atorvastatin and SNP. 
6.3 Materials and methods 
6.3.1 Materials 
The EBM-2 medium and supplements (vascular epidermal growth factor (VEGF), insulin-
like growth factor-1 (IGF-1), epidermal growth factor (EGF), fibroblast growth factor 
(FGF), hydrocortisone) were from Lonza (Verviers, Switzerland). Fetal calf serum (FCS), 
HEPES, Hank's balanced salt solution (HBSS), insulin, phosphate buffered saline (PBS), 
penicillin-streptomycin, sodium pyruvate and TGF-β1 were from Invitrogen (Basel, 
Switzerland). All culture plasticware and Transwell® filters were from Corning (Baar, 
Switzerland). [14C]-sucrose and Ultima Gold scintillation liquid was from Perkin Elmer 
(Schwerzenbach, Switzerland). Rat-tail collagen type I was from Becton Dickinson 
(Allschwil, Switzerland). Atorvastatin, bovine serum albumin (BSA), basic fibroblast 
growth factor (bFGF), cyclic adenosine monophosphate (cAMP), 2,7-dichlorofluorescin 
(DCFH), diclofenac, EGF, GDNF, heparin, hydrocortisone, indomethacin, minocycline, 
NAC, selenous acid, simvastatin, SNP and thalidomide were from Sigma (Buchs, 
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Switzerland). FluorSave was from Calbiochem (San Diego, CA, USA). Rabbit anti-ZO-1 
polyclonal antibody was purchased from Zymed (Basel, Switzerland). Cy2 conjugated 
goat anti-rabbit andtibody and Cy3 conjugated goat anti-rabbit andtibody were obtained 
from Jackson Immuno Research Laboratries (West Grove, PA, USA). IFN-β1b 
(Betaferon©, Schering, Zurich, Switzerland) was a kind gift of Prof. Dr. Kappos (University 
Hospital, Basel). 8-Br-cGMP was kindly provided by Prof. Dr. Resink (University Hospital, 
Basel). All other chemicals were purchased at the highest quality available. 
6.3.2 Cell culture 
For description see section 4.1. 
6.3.3 Incubation conditions for transport assays and immunocytochemistry 
To investigate the effect of test compounds on the [14C]-sucrose permeability and for 
immunostainings of ZO-1 the hCMEC/D3 cells were seeded on collagen coated 
Transwell® clear filters as described in section 4.5. Four and 7 days after the seeding the 
assay medium was changed and transport assays or immunostainings were performed 
after 10 days. The monolayers were incubated with the test compounds in different 
concentrations and for a defined time as summarized in Table 6.  
Test compound Concentrations Time (h) 
8-Br-cGMP 0.1, 0.5, 1 mM 24 
atorvastatin 1, 10, 100 ng/ml 72 
diclofenac 1, 5, 10 µM 72 
EGF 0.5, 1, 5 µg/ml 72 
GDNF ± cAMP 0.1, 1, 10 ng/ml 24 
heparin 10, 100, 1000 µg/ml 72 
IFN-β1b 50, 500, 1000 UI/ml 72 
IFN-β1b + minocycline IFN-β1b 500 UI/ml + minocycline 0.1, 100 µg/ml 72 
indomethacin 1, 5, 10 µM 72 
insulin 0.1, 1, 10 µg/ml 72 
minocycline 0.1, 10, 100 µg/ml 72 
NAC 5, 50, 100 µg/ml 72 
selenous acid 5, 10 µg/ml 72 
simvastatin 1, 10, 100 ng/ml 72 
SNP 100, 250, 500 µM 24 
TGF-β1 1, 5, 10 ng/ml 12 
thalidomide 0.1, 1, 10 µM 72 
Table 6 Concentrations and incubation times of test compounds. hCMEC/D3 cells were incubated 
as indicated for transport assays and immunocytochemistry. 
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6.3.4 Transport assay 
For description see section 4.5. 
6.3.5 Immunocytochemistry 
For immunostainings of ZO-1 hCMEC/D3 cells were seeded on type I collagen coated 
Transwell® polyester membranes (12 well, pore size 0.4 µm) in a concentration of 50’000 
cells/cm2. ZO-1 stainings were performed 10 days after seeding. The monolayers were 
incubated with atorvastatin (1 ng/ml), SNP (250 µM) and NAC (100 µg/ml) as described 
in section 6.3.3. 
Cells were washed twice with phosphate buffered saline (PBS) and the filter membranes 
were cut out. The cells were fixed with 4% paraformaldehyde for 10 min and were 
washed twice with PBS. Afterwards the cells were permeabilized in 0.5% Triton X-100 for 
5 min. After blocking with PBS containing 3% BSA the filters were incubated with the 
primary antibody against ZO-1 (rabbit anti-ZO-1, 20 µg/ml dissolved in PBS containing 
3% BSA) for 2 hours in a humid chamber at 37°C. Subsequently, the cells were washed 
3 times for 5 min with PBS followed by the incubation with the secondary antibody (goat 
anti-rabbit Cy3 labeled or goat anti-rabbit Cy2 labeled) in a concentration of 15 µg/ml 
dissolved in PBS containing 3% BSA for 1 hour at 20°C. Stained cells were washed 3 
times with PBS and the filter membranes were mounted on glass coverslides using 
FlourSafe. Fluorescence-stained cells were examined on a confocal Zeiss LSM 150 
inverted laser scanning microscope (Carl Zeiss, Oberkochen, Germany). For detection of 
the secondary Cy2 labeled antibody an argon laser at an excitation wavelength of 488 
nm was used and emission was measured at 510 nm. The detection of the Cy3 labeled 
secondary antibody was performed using an ArNe laser at an excitation wavelength of 
543 nm. Emission was measured using a bandpass filter (505-550nm). 
6.3.6 Reactive oxygen species (ROS) measurement 
6.3.6.1 ROS assay 
The generation of ROS was detected using the dye DCFH. DCFH is a non-fluorescent 
probe, which is oxidized by ROS to the fluorescent form 2,7-dichlorofluorescein (DCF). 
The cells were seeded on a type-I collagen precoated 96 well plate in concentration of 
10000 cells per cm2. Assay medium was changed every 3 or 4 days and 8 days after 
seeding the ROS assay was performed. After 4 hours of incubation with the supplements 
(see section 6.3.6.2) the medium was removed and cells were washed once with PBS. 
Thereafter, 100 µM DCF dissolved in assay medium were added and the plate was 
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incubated for 30 min at 37°C in an incubator. Subsequently the plate was measured 
using a HTS 7000plus plate reader with an excitation wavelength of 475 nm and an 
emission wavelength of 525 nm.  
6.3.6.2 Incubation conditions for ROS assay 
The hCMEC/D3 cells were incubated for 4 hours with assay medium containing 
atorvastatin (0.1, 1, 10, 100 ng/ml), NAC (5, 50, 100, 500, 1000 µg/ml), BSO (200 µM) 
and SNP (100, 250, 500 µM). H2O2 (0.1% in assay medium) was used as a positive 
control and assay medium containing 0.01% DMSO served as negative control. 
Previously the DCF fluorescence had been examined for assay medium alone and assay 
medium containing different DMSO concentrations (0.001, 0.01, 0.1%). No significant 
differences of DCF fluorescence intensity were observed (data not shown). 
6.3.7 Statistics 
For statistical comparison, data from the treatment groups were compared with those 
from the controls by analysis of variance (ANOVA) with subsequent Dunnett’s multiple 
comparison test. Where groups were compared, a pair-wise two-sided unpaired t-test 
was used. All comparisons were performed using SPSS for Windows software (version 
15.0, SPSS Inc. Chicago, IL, USA). 
6.4 Results 
6.4.1 Effects of test compounds on sucrose permeability 
As it is known from literature the paracellular resistance of the BBB depends on the 
correct assembly of the tight junction proteins. In vivo the correct assembly of tight 
junctional proteins is influenced by soluble factors released by surrounding astrocytes 
and pericytes as well as by blood-derived compounds. 
In order to increase the tightness of hCMEC/D3 monolayers the cells were incubated 
with the antioxidant drug NAC, the statins atorvastatin and simvastatin, SNP, the anti-
inflammatory drugs diclofenac, indomethacin and thalidomide, IFN-β1b, the glial cell-
derived growth factors (TGF-β1, GDNF, EGF), insulin, heparin, and selenous acid. After 
the incubation period transport of the radioactively labeled paracellular permeability 
marker [14C]-sucrose through hCMEC/D3 monolayers was measured. All assays were 
performed in duplicates or triplicates. For all transport experiments Pe values of [14C]-
sucrose in the range of 1.6 - 2.0 x 10-3 cm/min were used as internal standard. 
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Test substance Effect on Pe values of [14C]-sucrose n 
NAC Reduction by 12-18% (Figure 10) 9 
atorvastatin Reduction by 15% (Figure 11) 9 
SNP Reduction by 14% (Figure 12) 9 
IFN-β1b No significant change compared to control 9 
IFN-β1b + minocycline No significant change compared to control 6 
insulin No significant change compared to control 9 
TGF-β1 No significant change compared to control 9 
EGF No significant change compared to control 6 
GDNF ± cAMP No significant change compared to control 9 
Table 7 Effects of test compounds on Pe values of [14C]-sucrose in hCMEC/D3 cells. n: number of 
measured filters.  
Treatment of hCMEC/D3 monolayers with insulin (0.1, 1, 10 µg/ml) showed no change of 
[14C]-sucrose permeability. Also the growth factors EGF (0.5, 1, 5 µg/ml), TGF-β1 (1, 5, 
10 ng/ml) and GDNF (0.1, 1, 10 ng/ml) did not significantly improve the tightness of 
hCMEC/D3 monolayers against [14C]-sucrose, when applied to the culture medium dose-
dependently. The exposure of hCMEC/D3 cells to IFN-β1b alone (50, 500, 1000 UI/ml) or 
in combination with the metalloprotease inhibitor minocycline (0.1, 100 µg/ml) had no 
beneficial effect on the tightness of the cell monolayers.  
 
Figure 10 Effect of NAC (5, 50, 100 µg/ml) on the [14C]-sucrose permeability of hCMEC/D3 
monolayers. Data are means ± SEM of n=9 filters, *: p<0.05. 
The effect of the antioxidant drug NAC on the paracellular permeability was also 
investigated in a dose-dependent manner (5, 50, 100 µg/ml). The Pe values of [14C]-
sucrose after treatment with 5 and 50 µg/ml were 1.33*10-3 and 1.34*10-3 cm/min 
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respectively (Figure 10), whereas the control filters showed a Pe of 1.56*10-3 cm/min. This 
corresponds to a statistically significant reduction of the permeability coefficient by 14% 
at both NAC concentrations. The treatment with 100 µg/ml NAC reduced the Pe value by 
11% compared to the untreated control. However this decrease was statistically not 
significant.  
 
Figure 11 Effect of atorvastatin (1, 10, 100 ng/ml) on the [14C]-sucrose permeability of hCMEC/D3 
monolayers. Data are means ± SEM of n=9 filters, *: p< 0.05. 
Atorvastatin was applied to the hCMEC/D3 cells in 3 concentrations (1, 10, 100 ng/ml). 
At the low concentrations of 1 and 10 ng/ml the Pe values of [14C]-sucrose of 1.36*10-3 
and 1.38*10-3 cm/min respectively were measured (Figure 11). At both concentrations 
the Pe values of [14C]-sucrose permeability were reduced by 13% compared to the 
untreated control. However, only at the concentration of 1 ng/ml the sucrose permeability 
was statistically significant decreased. No altered permeability was observed after 
incubation with 100 ng/ml atorvastatin compared to the control. 
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Figure 12 Effect of SNP (100, 250, 500 µM) on the [14C]-sucrose permeability of hCMEC/D3 
monolayers. Data are means ± SEM of n=9 filters, *: p< 0.05. 
In another series of experiments hCMEC/D3 were grown on filters in the presence of 
different SNP concentrations (100, 250, 500 µM). Pe values after treatment with 100 µM 
and 500 µM SNP were 1.4*10-3 and 1.38*10-3 cm/min respectively (Figure 12). These 
values correspond to a reduction of [14C]-sucrose permeability of 14% at 100 µM and of 
15% at 500 µM SNP. However, these changes were not statistically significant. Only after 
treatment with 250 µM SNP the Pe value was statistically significant changed, where a Pe 
value of 1.3*10-3 cm/min was observed. This is a reduction of the [14C]-sucrose 
permeability of 20% compared to the untreated control filters. 
6.4.2 Preliminary results 
Test compound Effect on Pe values of [14C]-sucrose n 
minocycline No significant change compared to control 3 
heparin No significant change compared to control 3 
8-Br-cGMP No significant change compared to control 3 
indomethacin No significant change compared to control 3 
simvastatin No significant change compared to control 3 
diclofenac No significant change compared to control 3 
thalidomide No significant change compared to control 3 
selenous acid No significant change compared to control 3 
Table 8 Preliminary results: Effects of test compounds on Pe values of [14C]-sucrose in 
hCMEC/D3 cells.  
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In a series of experiments dose-dependent incubations with the three anti-inflammatory 
drugs indomethacin (1, 5, 10 µM), diclofenac (1, 5, 10 µM) and thalidomide (0.1, 1, 10 
µM), 8-Br-cGMP (0.1, 0.5, 1 mM), selenous acid (5, 10 µg/ml), heparin (10, 100, 1000 
µg/ml), simvastatin (1, 10, 100 ng/ml) and minocycline (0.1, 10, 100 µg/ml) were 
performed. None of these supplements did alter the [14C]-sucrose permeability to a 
significant extent. However, these are only preliminary results and further experiments 
are necessary to validate these findings. 
6.4.3 Intracellular ROS measurement 
The effect of ROS generation was investigated in hCMEC/D3 cells, using DCFH. The 
non-fluorescent compound DCFH is oxidized by ROS to a fluorescent probe (DCF). The 
fluorescence intensity correlates with the intracellular ROS production. Since H2O2 is 
known to induce intracellular ROS generation it served as a positive control in a 
concentration of 0.1%. In our experiments H2O2 increased the ROS production by 275%. 
Additionally, the cells were incubated with 0.1% H2O2 in combination with NAC (500 
µg/ml), atorvastatin (0.1 ng/ml) and SNP (250 µM). These three supplements did not 
decrease the H2O2 induced generation of ROS (Figure 13).  
 
Figure 13 ROS production in hCMEC/D3 cells after 4 h of incubation with 0.1% H2O2. Data are 
means ± SEM of n=4; *: p<0.05. 
Treatment of the cells with NAC (5, 50, 100, 500, 1000 µg/ml) for 4 hours resulted in a 
dose-dependent decrease of ROS production (Figure 14). The reduction of ROS 
generation was statistically significant at all tested NAC concentrations. Compared to the 
untreated control the DCF fluorescence was reduced by 46% after treatment with the 
lowest NAC concentration (5 µg/ml), whereas the highest NAC concentration (1000 
µg/ml) reduced the DCF fluorescence by 65%.  
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Figure 14 ROS production in hCMEC/D3 cells after 4 h of incubation with NAC (5, 50, 100, 500, 
1000 µg/ml). Data are means ± SEM of n=4; *: p<0.0005. 
Figure 15 shows a curve-fit and the calculated ED50 value (half maximal effect) of the 
reduced ROS generation after the dose-dependent NAC treatment. The ED50 of NAC 
was observed at a concentration of 1.91 µg/ml. 
 
Figure 15 ED50 curve of ROS production in hCMEC/D3 cells. ED50 of NAC = 1.91 µg/ml. Data are 
means ± SEM of n=4. 
Dose-dependent incubations with SNP (100, 250, 500 µM) decreased the ROS 
generation in hCMEC/D3 cells significantly (Figure 16). At a concentration of 250 µM 
SNP the DCF fluorescence intensity was reduced by 47% compared to the untreated 
control. In contrast, dose-dependent treatment of the cells with atorvastatin (0.1, 1, 10, 
50 
100 ng/ml) was not associated with a decrease in ROS generation (Figure 17). 
 
Figure 16 ROS production in hCMEC/D3 cells after 4 h of incubation with SNP (100, 250, 500 
µg/ml). Data are means ± SEM of n=4; *: p<0.0005. 
 
Figure 17 ROS production in hCMEC/D3 cells after 4 h of incubation with atorvastatin (0.1, 1, 10, 
100 ng/ml). Data are means ± SEM of n=4. 
6.4.4 Immunostaining of ZO-1 under influence of NAC, SNP and atorvastatin  
Immunostainings of ZO-1 in hCMEC/D3 cells were performed in the presence of NAC, 
SNP and atorvastatin using the polyclonal antibody (rabbit anti ZO-1) against ZO-1. An 
intense staining was observed in the untreated control cells as shown in Figure 18 
indicating the expression of ZO-1. The strongest intensity was found at the cell borders, 
but also a cytosolic staining of weaker intensity was observed. After treatment with NAC 
in a concentration of 100 µg/ml an altered ZO-1 expression pattern was observed. The 
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cells showed a generally stronger staining of ZO-1 compared to the control cells. ZO-1 
expression was not only increased at the cell borders but also in the cytosol. 
Furthermore, the treated cells showed a more homogeneous morphological structure 
than the untreated control cells. Treatment of hCMEC/D3 cells with SNP (250 µM) and 
atorvastatin (1 ng/ml) caused also an increase in ZO-1 expression at the cells borders as 
well as within the cells. 
 
Figure 18 Confocal laser microscopy pictures of ZO-1 in hCMEC/D3 cells under different 
incubation conditions (40x magnification, A-C secondary Cy2 labeled AB goat anti-rabbit, D-E 
secondary Cy3 labeled AB goat anti-rabbit). A: untreated control of SNP and atorvastatin, B: 24h 
incubation with 250 µM SNP, C: 72h incubation with 1 ng/ml atorvastatin, D: untreated control of 
NAC, E: 72h incubation with 100 µg/ml NAC. 
6.5 Discussion 
The human BBB formed by endothelial brain capillary cells is characterized by a low 
paracellular permeability. TJs seal the intercellular gaps and restrict the passive diffusion 
of hydrophilic compounds. Therefore, low paracellular permeability is a crucial feature for 
every in vitro model of the BBB in order to perform transport studies. In this study the 
recently developed hCMEC/D3 cell line was used as an in vitro model of the human BBB. 
The hCMEC/D3 cells exhibit important BBB characteristics such as the expression of TJ 
molecules, chemokine receptors, drug efflux transporters and a low permeability (given 
as Pe) for the small hydrophilic tightness marker sucrose (Weksler et al. 2005; Poller et 
al. 2008). It was demonstrated that replacing FCS by human serum reduced significantly 
the sucrose permeability in the hCMEC/D3 (Poller et al. 2008).  In addition it is known 
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that the molecular composition of TJs can be modulated under physiological and 
pathophysiological conditions leading to permeability changes (Abbott et al. 2006). 
Therefore, the aim of the present study was to reduce the paracellular permeability of 
hCMEC/D3 line monolayers by different medium supplements such as anti-inflammatory 
drugs, growth factor or antioxidants. 
In an in vivo rat model a disruption of the BBB was observed after injection of the pro-
inflammatory cytokine TNF-α. The barrier breakdown was accompanied by an induction 
of cyclooxygenase-2 (COX-2). The BBB disruption as well as the COX-2 up-regulation 
could be inhibited with the unspecific COX-inhibitor indomethacin (Candelario-Jalil et al. 
2007).  Therefore, we investigated the effect of indomethacin, the more COX-2 specific 
inhibitor diclofenac, and the TNF-α antagonist thalidomide on the tightness of hCMEC/D3 
monolayers. The anti-inflammatory drugs were applied at pharmacological 
concentrations. In our preliminary experiments we did not observe an improvement of 
BBB tightness with any of the examined anti-inflammatory compounds. In our model the 
cells were maintained in absence of an inflammatory stimulus. This observation 
corresponds to the recently published data of Cucullo et al. In their dynamic in vitro BBB 
model using the hCMEC/D3 cell line, flow cessation and reperfusion caused a biphasic 
opening of the BBB. Pre-treatment with ibuprofen partially prevented BBB opening, 
whereas control cells under flow treated with ibuprofen showed no change in 
transendothelial resistances (Cucullo et al. 2008). 
IFN-β1b is the standard treatment for patients with relapsing-remitting multiple sclerosis. 
During the relapses a breakdown of the BBB occurs followed by leukocyte infiltration into 
the brain and a demyelization process (Kraus and Oschmann 2006). The breakdown is 
likely to be caused by effects of soluble inflammatory mediators such as interferon-γ 
(IFN-γ), TNF-α, interleukin-1β, MMP-7, MMP-9 and nitric oxide. In contrast, IFN-β1b has 
a stabilizing effect on the BBB and leads to a down-regulation of pro-inflammatory 
cytokines and to an up-regulation of anti-inflammatory cytokines. Furthermore, it could be 
demonstrated that IFN-β1b reduces the permeability of inulin and sucrose through 
monolayers of primary bovine BCEC in vitro (Kraus et al. 2004). In our experiments IFN-
β1b was applied to the hCMEC/D3 cells at pharmacological concentrations. No reduction 
of sucrose permeability at any of the used concentration was observed. None of the 
concentrations of IFN-β1b did significantly lower the sucrose Pe values in comparison to 
the control cells. This might be caused by the absence of an inflammatory stimulus in the 
hCMEC/D3 cells. Further investigations are needed to clarify this question.  
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MMPs, mainly MMP-7 and MMP-9 are involved in the acute breakdown of the BBB 
during relapses of multiple sclerosis. They degrade the collagen of the basal lamina, 
which is the basement of the endothelial cells (Yang et al. 2005). Furthermore, MMPs 
can cleave IFN-β1b, which is used for the therapy of multiple sclerosis, resulting in a 
reduced efficacy of the therapy. Minocycline a member of the tetracycline antibiotics is an 
inhibitor of the MMPs with high potency for MMP-9 (Brundula et al. 2002; Nelissen et al. 
2003). In our experiments, we did not observe reduced sucrose permeability after 
incubating the hCMEC/D3 cells with minocycline. Also sucrose Pe values of cells treated 
with the combination of minocycline and IFN-β1b were not significantly different from 
controls. These findings might indicate that the MMPs had no negative effect on the 
monolayer or were not released at sufficient levels.  
In vivo the BCEC are surrounded by astrocytes and pericytes. These cells release 
growth factors that modulate formation of the TJs (Abbott et al. 2006). It was shown that 
TGF-β1 a soluble factor produced by pericytes, could reduce sodium fluorescin 
permeability in the MBEC4 mouse cell line (Dohgu et al. 2005). GDNF is another soluble 
growth factor, which is released by glial cells that surround BCEC. In a previous 
publication GDNF induced an immediate increase in transendothelial resistance of 
primary porcine BCEC monolayers (Igarashi et al. 1999). The effect was only observed 
when GDNF was applied in the presence of the cAMP analogue CPT-cAMP in 
combination with the phosphodiesterase inhibitor, RO20-1724. In the hCMEC/D3 cell line 
TGF-β1 and GDNF were investigated at the same concentrations as described by Dohgu 
et al. and Igarashi et al. However, no reduction of sucrose permeability was observed in 
the hCMEC/D3 cells in our experiments. Furthermore, no decrease of sucrose 
permeability compared to the control was observed when GDNF was added either alone 
or in combination with the cAMP analogue.  
Recently, it has been found that the BBB in rats became leaky for small molecular weight 
molecules during a streptozotocin-induced period of diabetes. The observed disruption 
could partly be prevented under insulin treatment (Huber et al. 2006; Hawkins et al. 
2007). However, our study revealed no permeability decreasing effects of insulin on 
hCMEC/D3 monolayers. For our experiments the cells were not maintained under 
hyperglycemic conditions. This fact might explain why the supplementation with insulin 
did not improve the tightness of the hCMEC/D3 cells.  
Based on a publication of Franke et al. (Franke et al. 1999) we also investigated the 
effect of selenous acid and the growth hormone EGF on the hCMEC/D3 cells. In the 
model of Franke et al., using isolated primary porcine BCEC, high electrical resistances 
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were reported while EGF and selenous acid were contained in the culture medium. 
However, it was not shown if these supplements were necessary in order to reach high 
electrical resistances. Although applied at the same concentration range as published, 
selenous acid and EGF had no beneficial effect on the monolayer tightness in our model.  
The data obtained from selenous acid experiments are preliminary. 
Heparin is also a common medium supplement which has been used in different models 
of the BBB (Gaillard et al. 2001; Megard et al. 2002). So far there are no studies that 
investigated the effect of heparin on the paracellular permeability of BCECs. In our 
preliminary experiment, no beneficial effect on the monolayer tightness was observed, 
when heparin was added to the culture medium.   
Recently, the generation of ROS was described to disrupt the integrity of the BBB in vitro. 
Schreibelt et al. observed a reduced expression of the TJ molecules occludin and 
claudin-5 and a decreased transendothelial resistance of confluent monolayers. The 
human and rat cell lines hCMEC/D3 and GP8 respectively served as models of the BBB 
(Schreibelt et al. 2007). Our aim was to investigate if antioxidant compounds can improve 
the integrity of hCMEC/D3 monolayers. Therefore, the cells were treated with 
compounds that are described to reduce the generation of ROS such as SNP, 
atorvastatin, simvastatin and NAC. 
In endothelial cells NO is generated by the nitric oxide synthase (NOS), where it 
regulates the blood flow through the activation of NO-sensitive guanylyl cyclases and the 
generation of cycliyc guanosin monophosphate (cGMP). Furthermore, based on its 
structure as a free radical, NO can scavenge ROS by reactions of unpaired electrons 
(Chiueh 1999). By binding to iron complexes NO also reduces the production of ROS 
that are generate during redox reaction in the respiratory chain (Chiueh 1999; Foster et 
al. 2003).  
Effects of NO releasing compounds on permeability properties have been investigated in 
different models of the BBB. The changes of permeability depend on the redox state of 
NO (NO(*), NO(+), NO(-)) released by the donor compound. Whereas NO(+) and NO(-) 
cause a disruption of the BBB in rats, no permeability changes are reported for the NO(*) 
radical (Boje and Lakhman 2000). In vitro NO(*) releasing compounds had decreased the 
permeability of isolated primary porcine BCEC monolayers (Winter et al. 2008). SNP 
being also a member of the NO(*) radical releasing compounds was reported to increase 
the tightness of monolayers of primary human BCEC. It was postulated that the 
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production of cGMP by the guanylyl cyclase and activation of cGMP-dependent protein 
kinase were involved in the observed process (Wong et al. 2004).  
For that reason, we investigated the effect of SNP in our hCMEC/D3 model.  After 
treatment with SNP in a concentration of 250 µM the sucrose permeability was 
significantly reduced. To investigate if this effect was cGMP-depended the hCMEC/D3 
cells were incubated with 8-Br-cGMP, a cGMP-analogue. However, 8-Br-cGMP did not 
affect the tightness in our model. 
Based on the antioxidant effects of NO(*) we investigated the effect of the NO-releaser 
SNP on the generation of ROS in the hCMEC/D3 cells. After treatment with SNP (250 
µM) a significantly reduced DCF fluorescence was measured compared to control cells, 
indicating reduced intracellular ROS levels compared to the control. This result supports 
the thesis that NO exerts protective effects on the BBB based on its antioxidant 
properties.  
In a next step the expression of ZO-1 under influence of SNP was investigated by 
immunocytochemistry. A generally more intense staining of ZO-1 was observed 
compared to the untreated control cells. However, ZO-1 was not only increased at the 
cell borders but also in the cytosol.  
Recent studies revealed evidence that statins stabilize the BBB. It was shown that 
lovastatin, simvastatin and fluvastatin decreased the tightness of BCEC monolyers in 
vitro (Ifergan et al. 2006; Kuhlmann et al. 2006). Furthermore, statins exert anti-
inflammatory effects by reducing the expression of cytokines such as TNF-α and 
interleukin-6 (Youssef et al. 2002). Statins also show antioxidant properties such as 
reducing lipoprotein oxidation and the generation of ROS (Vaughan and Delanty 1999). 
In our study the influence of atorvastatin and simvastatin on the monolayer tightness was 
investigated. In addition, the effect of atorvastatin on the generation of ROS and the 
protein expression of ZO-1 was assessed. When applied at pharmacological 
concentrations atorvastatin significantly decreased the sucrose permeability in the 
hCMEC/D3 cell line. In contrast sucrose Pe values were not affected by treatment with 
simvastatin. 
Therefore, we investigated the generation of ROS in the hCMEC/D3 cells after treatment 
with atorvastatin. In a preliminary experiment no statistically significant decrease of ROS 
generation was observed compared to the untreated control. This result indicates that 
reduced paracellular permeability caused by atorvastatin is not dependent on antioxidant 
effects. However, these preliminary results need to be confirmed. 
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In a next step, the expression of ZO-1 was investigated after atorvastatin treatment using 
immunocytochemistry. Compared to untreated control cells atorvastatin caused a 
generally stronger staining of ZO-1, indicating an increased protein expression. However, 
ZO-1 expression was increased at the cell border as well as in the cytosol. An increased 
ZO-1 expression at the cells borders might lead to a higher paracellular resistance of the 
model. 
Another known antioxidant agent and radical scavenger is NAC, which protects cells 
against OH radicals and H2O2. NAC is a derivative of the amino acid cysteine, which is 
an essential precursor for the synthesis of glutathione (GSH). Consequently 
deacetylation of NAC increases the intracellular level of cysteine and GSH, which in turn 
is responsible for maintaining the cellular redox status in endothelial cells and provides 
antioxidant protection against ROS. Therefore, NAC has a highly antioxidant potential, 
which was shown in several studies (Townsend et al. 2003; Atkuri et al. 2007). An 
structure analogue of NAC was shown to reduce the ROS generation in brain endothelial 
cells (Price et al. 2006).  
Based on these properties, we investigated the effect of NAC on the paracellular 
tightness in the hCMEC/D3 cell line by determining the sucrose permeabilty. The Pe 
values for sucrose after NAC treatment in a concentration of 50 µg/ml and 5 µg/ml were 
significantly reduced as compared to the control. 
We also investigated the hypothesis that ROS production is reduced after NAC 
treatment. Therefore, we determined the intracellular ROS generation in hCMEC/D3 
cells. Treatment with NAC resulted in a dose-dependent decrease of DCF production. 
The greatest reduction was observed at a NAC concentration of 1000 µg/ml. The ED50 
value of NAC was calculated at a concentration of 1.91 µg/ml. H2O2, a well-known ROS 
producer, served as a positive control for the generation ROS measurement the cells 
(Arbogast and Reid 2004). Compared to the control H2O2 induced ROS generation in our 
experiment by 275%.  However, this induction was not reversible by adding NAC, 
atorvastatin or SNP. Possibly, the H2O2 induced intracellular ROS generation was too 
high to be suppressed by the NAC. 
ZO-1 immunostainings were performed in order to assess the effect of NAC on the 
molecular assembly of tight junctions. At a concentration of 100 µg/ml NAC the staining 
of ZO-1 was more intense indicating higher expression levels. As observed for treatment 
with atorvastatin the ZO-1 expression was increased at cell borders as well as in the 
cytosol, may giving an indication for a higher resistance of the model. 
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In conclusion, we could demonstrate that the antioxidant compounds NAC, SNP and 
atorvastatin reduced the permeability of the paracellular marker sucrose in the 
hCMEC/D3 cell line. Furthermore, we showed a suppressed generation of ROS and 
increased levels of ZO-1 under influence of NAC and SNP, which indicates that 
intracellular ROS levels might influence the composition of TJ. However, information on 
other tight junctional components is needed to conclusively determine this question. 
All other tested compounds including the anti-inflammatory drugs diclofenac, 
indomethacin and thalidomide, IFN-β1b, the glial cell-derived growth factors (TGFβ1, 
GDNF, EGF), insulin, heparin, and selenous acid, had no effect on the permeability of 
hCMEC/D3 monolayers. 
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7.1 Abstract 
Brain capillary endothelial cells form the blood-brain barrier (BBB), a highly selective 
permeability membrane between the blood and the brain. Tight junctions that prevent 
small hydrophilic compounds from passive diffusion into the brain tissue and endothelial 
cells express different families of drug efflux transport proteins that limit the amount of 
their substrates that can penetrate the brain. Two prominent efflux transporters are the 
breast cancer resistance protein (BCRP) and P-glycoprotein (P-gp). During inflammatory 
reactions, which are associated with various diseases, pro-inflammatory cytokines are 
present in the systemic circulation. In this study the effect of the pro-inflammatory 
cytokines interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) 
on the expression and activity of BCRP and P-gp was investigated in the human 
hCMEC/D3 cell line. BCRP mRNA levels were significantly reduced by IL-1β, IL-6 and 
TNF-α. The strongest BCRP suppression at the protein level was observed after IL-1β 
treatment. IL-1β, IL-6 and TNF-α significantly reduced the BCRP activity as assessed by 
mitoxantrone uptake experiments. P-gp mRNA levels were slightly reduced by IL-6 but 
significantly increased after TNF-α treatment. TNF-α also increased the protein 
expression of P-gp. 
This in vitro study indicates that expression levels of BCRP and P-gp at the BBB might 
be altered during acute or chronic inflammation, resulting in changes in the extent to 
which their substrates can penetrate the brain.  
7.2 Introduction 
The brain capillary endothelial cells (BCEC) are the main constituents the blood-brain 
barrier (BBB), a highly selective permeability barrier that protects the brain tissue from 
infiltration of potentially toxic compounds and xenobiotics from the bloodstream. The 
passive diffusion of hydrophilic molecules into the brain is thereby prevented by tight 
junctions, which seal the monolayer of the endothelial cells. Furthermore, various drug 
efflux-transporters are located at the BBB and extrude their substrates from the brain by 
an active transport process. These transporters belong to the superfamilies of ATP-
binding cassette transporters (ABC-transporters) and solute carriers (SLC). Two 
prominent and well characterized representatives of the ABC-transporters are the breast 
cancer resistance protein (BCRP or ABCG2) and P-glycoprotein (P-gp or ABCB1) 
(Schinkel and Jonker 2003). 
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BCRP is expressed at the apical plasma membrane of the BBB, as documented for the 
human, porcine and mouse BBB (Cooray et al. 2002; Eisenblatter and Galla 2002; 
Eisenblatter et al. 2003; Cisternino et al. 2004). This transporter has been shown to be 
involved in the transport of drugs such as mitoxantrone, prazosin and topotecan, 
anthracyclines and food carcinogens (reviewed in (Loscher and Potschka 2005)). The 
relevance of BCRP transport in vivo was shown in a mdr1a(-/-) knock-out mouse model. 
By blocking BCRP with specific inhibitors, the brain uptake of mitoxantrone and prazosin 
was significantly increased, demonstrating that BCRP, and not P-gp, was involved 
(Cisternino et al. 2004).  
P-gp was the first efflux transporter to be described at the human BBB (Cordon-Cardo et 
al. 1989). It is expressed at the apical membrane of BCECs, where it limits the brain 
uptake of a broad range of clinically used compounds such as anticancer drugs, 
corticosteroids or antiepileptic drugs (Schinkel et al. 1995; Loscher and Potschka 2005). 
The relevance of P-gp at the BBB was shown in mdr1a(-/-) knock-out mice. The absence 
of the transporter leads to highly increased brain levels of drugs such as digoxin, 
vinblastine, cyclosporine A or domperidone (Schinkel et al. 1996). The clinical relevance 
of this transporter is well documented (Lin and Yamazaki 2003). 
Inflammation is associated with a variety of diseases, including central nervous system 
disorders such as multiple sclerosis, bacterial meningitis, Alzheimer’s disease and 
Parkinson’s disease. During these diseases, several changes in the morphology and 
permeability of the BBB have been described (de Vries et al. 1997; Huber et al. 2001; 
Reale et al. 2008). Cytokines are the mediators of the inflammation and high levels of 
tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6) are 
present in the brain tissue or in the systemic blood circulation during acute inflammation. 
In cell culture models, these cytokines were shown to disrupt the integrity of the BBB (de 
Vries et al. 1996; Forster et al. 2008).  
The influence of inflammation or single cytokines on the expression of ABC-transporters 
has been investigated in tissue samples from patients and in in vitro cell culture systems. 
P-gp and BCRP, for example, are expressed at significantly lower levels during active 
inflammation in colonic epithelium from patients with ulcerative colitis, while expression 
levels of IL-1β and IL-6 mRNA were higher in biopsies from actively inflamed tissue 
compared to healthy controls (Englund et al. 2007; Gutmann et al. 2008). In primary 
placental trophoblasts, TNF-α and IL-1β decreased the mRNA and protein expression of 
P-gp and BCRP by 40-50% (Evseenko et al. 2007). At the BBB, there are only very 
limited data concerning BCRP expression and controversial reports on the regulation of 
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P-gp under influence of TNF-α exist. There are reports showing P-gp mRNA or protein 
up-regulation, whereas other studies observed a decreased P-gp function. However, the 
systems used for the investigations varied greatly (Theron et al. 2003; Bauer et al. 2007; 
Seelbach et al. 2007). 
The human hCMEC/D3 cell line, which shows a very similar morphology to primary 
human BCECs and expresses important BBB markers such as junctional molecules, 
chemokine receptors and ABC-transporters served as an in vitro model of the human 
BBB (Weksler et al. 2005; Poller et al. 2008). 
It was the aim of the present work to investigate the impact of the pro-inflammatory 
cytokines IL-1β, IL-6 and TNF-α on the expression of the ABC-transporters P-gp and 
BCRP. Modulatory effects were determined on the mRNA and protein level. Furthermore, 
the functional activity of BCRP was investigated by measuring cellular efflux experiments 
using BCRP substrate mitoxantrone. 
7.3 Materials and methods 
7.3.1 Materials 
The EBM-2 medium and supplements (vascular endothelial growth factor (VEGF), 
insulin-like growth factor (IGF-1), epidermal growth factor (EGF), basic fibroblast growth 
factor (bFGF) and hydrocortisone) were purchased from Lonza (Verviers, Switzerland). 
All culture plasticware and Transwell® filters were from Corning (Baar, Switzerland). Rat-
tail collagen type I was from Becton Dickinson (Allschwil, Switzerland). Fetal calf serum 
(FCS), bFGF, DNAse I, Hanks’ balanced salt solution (HBSS), HEPES, penicillin-
streptomycin, sodium pyruvate and SuperScript II RT-Kit were from Invitrogen (Basel, 
Switzerland). RNeasy Mini Kit was purchased from Qiagen (Hilden, Germany). qPCR 
Mastermix Plus was from Eurogentec (Seraing, Belgium). Random hexamers were from 
Applied Biosystems (Rotkreuz, Switzerland). dNTPs were from BioRad (Reinach, 
Switzerland). The murine antibody (mAb) C219 against P-gp and the mAb BXP-21 
against BCR were from Alexis (Lausen, Switzerland). Rabbit anti-mouse IgG was from 
Dako (Baar, Switzerland). bFGF, hydrocortisone, IL-1β, Il-6, mitoxantrone and TNF-α 
were from Sigma (Buchs, Switzerland). FluorSave was from Calbiochem (San Diego, 
CA, USA). All other chemicals were of analytical grade and purchased from commercial 
sources. 
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7.3.2 Cell culture 
For description see section 4.1. 
7.3.3 Incubation conditions for the pro-inflammatory cytokines TNF-α, IL-1β, IL-6 
The cell culture medium was replaced with FCS-reduced assay medium (0.25% instead 
of 2.5%) 24 h before the beginning of the incubation period. Then the hCMEC/D3 cells 
were treated with TNF-α (2, 20 ng/ml), IL-1β (0.2, 2 ng/ml), IL-6 (2, 20 ng/ml) in FCS-
reduced assay medium for 72 h. Control cells were maintained in FCS-reduced assay 
medium. The medium for all treatments was replaced every 24 h. Toxicity was tested in 
advance for all applied substances using sulforhodamine B staining according to Skehan 
et al. (Skehan et al. 1990). 
7.3.4 Quantitative RT-PCR TaqMan assay 
For description see section 4.2. 
7.3.5 Western Blot 
For description see section 4.4. 
7.3.6 Drug accumulation assay 
For description see section 4.6. 
7.3.7 Statistics 
Data from the treatment groups were compared with those from the controls by analysis 
of variance (ANOVA) with subsequent Dunnett’s multiple comparison test. All 
comparisons were performed using SPSS for Windows software (version 15.0, SPSS 
Inc., Chicago, IL, USA). 
7.4 Results 
7.4.1 Influence of IL-1β, IL-6 and TNF-α on BCRP and P-gp mRNA expression 
hCMEC/D3 cells were treated with the pro-inflammatory cytokines IL-1β, IL-6 and TNF-α 
for 72 h. As shown in Figure 19, BCRP mRNA expression was reduced significantly in 
cells treated with IL-1β, IL-6 and TNF-α. The strongest down-regulation of BCRP mRNA 
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(by 45%) was observed under IL-6 treatment. IL-1β and TNF-α exhibited a reduction of 
BCRP gene expression by 33% and 31% compared to the untreated control cells. 
 
Figure 19 Relative expression of BCRP mRNA normalized to GAPDH in hCMEC/D3 cells. Data 
are given as means of n=6-9 ± SEM (***: p<0.0005). 
The P-gp mRNA expression was measured after 72 h of incubation with IL-1β, IL-6 and 
TNF-α in hCMEC/D3 cells as shown in Figure 20. P-gp was down-regulated by 14% after 
treatment with IL-1β and by 21% after treatment with IL-6. In contrast incubation of the 
cells with TNF-α resulted in a highly significant increase in P-gp mRNA expression by 
49% compared to the control cells. 
 
Figure 20 Relative expression of P-gp mRNA normalized to GAPDH in hCMEC/D3 cells. Data are 
given as means of n=6-9 ± SEM (*: p<0.05, ***: p<0.0005). 
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7.4.2 Influence of IL-1β, IL-6 and TNF-α on BCRP and P-gp protein expression 
Expression levels of BCRP and P-gp in hCMEC/D3 cells were determined on protein 
level by Western blot analysis, shown in Figure 21. Immunoblotting was performed after 
a 72 h incubation of hCMEC/D3 cells with IL-1β, IL-6 and TNF-α. Equal protein loading 
was checked by Ponceau red staining after the transblot and only samples with equal 
protein content were compared. For BCRP, a very slight down-regulation compared to 
the control was observed after treatment with IL-6. The down-regulation was more 
pronounced with IL-1β and TNF-α. The protein levels of P-gp were not changed under 
influence of IL-6 and IL-1β. TNF-α exerted a clear increase in P-gp protein expression.  
 
Figure 21 Protein expression of BCRP and P-gp in hCMEC/D3 cells under influence of reference 
treatment (A), IL-6 (B), IL-1β (C) and TNF-α (D). 
7.4.3 Mitoxantrone (MX) accumulation under influence of cytokines 
To confirm that the cytokine-induced changes in BCRP mRNA expression are also 
reflected in an altered transport function, efflux studies were performed using the BCRP 
substrate mitoxantrone. Prior to the drug accumulation experiments the hCMEC/D3 cells 
were incubated for 72 h with IL-1β, IL-6 and TNF-α. The BCRP inhibitor prazosin was 
used as a positive control. An increase in the MX accumulation by 11% was observed in 
the presence of prazosin as shown in Figure 22.  Pretreatment with IL-1β at a 
concentration of 2 ng/ml caused a statistically significant increase in intracellular MX 
amount by 57% in hCMEC/D3 cells compared to the control. At a concentration of 0.2 
ng/ml the intracellular MX showed a not statistically significant elevation of 22% as 
compared to control.  
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Figure 22 Accumulation of MX in hCMEC/D3 cells after 72 h pretreatment with IL-1β (0.2, 2 
ng/ml), in percent of control. Data are given as means of n=8 ± SEM (***: p<0.0005). 
Pretreatment of the hCMEC/D3 cells with IL-6 resulted in significantly higher intracellular 
MX amounts as compared to untreated control cells (Figure 23). At a concentration of 2 
ng/ml IL-6 the accumulation was increased by 120% and at a concentration of 20 ng/ml 
IL-6 by 96%. Acute prazosin inhibition reduced the BCRP-mediated MX efflux in 
untreated hCMEC/D3 cells and resulted in a significantly higher intracellular MX 
accumulation (80%) as compared to the control.  
 
Figure 23 Accumulation of MX in hCMEC/D3 cells after 72 h pretreatment with IL-6 (2, 20 ng/ml), 
in percent of control. Data are given as means of n=7-9 ± SEM (*: p<0.05, **: p<0.005, ***: 
p<0.0005). 
66 
After incubation of hCMEC/D3 cells with TNF-α at concentrations of 2 and 20 ng/ml a 
significantly higher MX accumulation was observed as compared to the control cells 
(Figure 24). At a TNF-α concentration of 2 ng/ml and 20 ng/ml the intracellular MX 
amount was increased by 96% and 69%, respectively. Only at a concentration of 2 ng/ml 
was a statistically significant increase observed. Prazosin inhibited the MX efflux in 
untreated cells, resulting in a 53% higher intracellular accumulation as compared to the 
control. 
 
Figure 24 Accumulation of MX in hCMEC/D3 cells after 72 h pretreatment with TNF-α (2, 20 
ng/ml), in percent of control. Data are given as means of n=7-9 ± SEM (*: p<0.0005). 
7.5 Discussion 
In this study, the effect of the pro-inflammatory cytokines IL-1β, IL-6 and TNF-α on 
expression and function of the ABC-transporters BCRP and P-gp was investigated using 
an in vitro model of the human BBB, namely the immortalized human brain endothelial 
cell line hCMEC/D3. These cells were shown previously to preserve many characteristics 
of the BBB. In particular, functional expression of several ABC-transporters was shown 
including the well characterized BCRP and P-gp (Poller et al. 2008).  
Up to now, little was known about the influence of the pro-inflammatory cytokines on the 
expression of BCRP, especially at the level of the BBB. In two studies, mRNA and 
protein expression of BCRP and P-gp was measured in colon biopsies from patients with 
ulcerative colitis (Englund et al. 2007; Gutmann et al. 2008). Both studies found a 
significant down-regulation of BCRP and P-gp in inflamed tissue. Englund et al. also 
reported markedly increased mRNA levels of IL-1β and IL-6 in inflamed tissue. The 
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authors of both studies concluded that the suppression of BCRP and P-gp expression 
was likely to be caused by the inflammatory process. In primary placental trophoblasts 
the same concentrations of IL-1β and TNF-α as used in our study reduced the BCRP 
mRNA expression (Evseenko et al. 2007). Similar findings were obtained in the present 
study, which showed a significant down-regulation of BCRP and P-gp in a cell-culture 
model of the BBB. In the latter study, down-regulation of mRNA by TNF-α resulted in a 
reduced functional activity of BCRP as demonstrated by an increased accumulation of 
MX. The authors showed, in addition that IL-6 caused a weak but insignificant down-
regulation of BCRP (Evseenko et al. 2007). At the BBB level, there exists a diverging 
report that TNF-α does not change the Bcrp protein expression in freshly isolated rat 
brain capillaries (Bauer et al. 2007). In contrast to Bauer et al. we observed a down-
regulation of BCRP expression in the hCMEC/D3 cells. However, compared to Bauer et 
al. the TNF-α concentration used for our studies was higher (1 ng/ml vs. 20 ng/ml TNF-α 
in this study) and the incubation period was longer (3-6 h vs. 72 h in this study), which 
may explain the difference. The reduction in BCRP mRNA expression in the hCMEC/D3 
cells was reflected in the protein level even though it was not very pronounced. However, 
a significantly reduced intracellular accumulation of the BCRP substrate MX was 
observed under influence of each of the tested cytokines, indicating reduced BCRP 
activity. MX efflux was reduced to a similar magnitude in cells pre-treated with the 
cytokines as in untreated cells inhibited with prazosin during the efflux period.  Compared 
to findings in primary trophoblasts, 20 ng/ml TNF-α increased the intracellular MX 
accumulation in the hCMEC/D3 cells to a greater extent (70% vs 15%) (Evseenko et al. 
2007). This might be explained by a higher basal expression level of BCRP at the BBB 
compared to primary trophoblasts.  
P-gp mRNA and protein expression were significantly up-regulated after treatment with 
TNF-α, whereas IL-1β and by IL-6 did not change P-gp expression levels. The effect of 
the pro-inflammatory cytokines, in particular TNF-α, on the expression of P-gp is 
discussed controversially. In the study of Englund et al. the down-regulation of BCRP 
was accompanied by a suppression of P-gp mRNA and protein, while IL-1β and IL-6 
mRNA levels were elevated (Englund et al. 2007). In isolated primary placental 
trophoblasts a down-regulation of P-gp under the influence of TNF-α and IL-1β was also 
reported (Evseenko et al. 2007). In BCEC several studies observed an increased P-gp 
expression after exposure to TNF-α corroborating our finding. In the GPNT mouse BBB 
cell line, 10 ng/ml TNF-α caused an increase in mdr1a after 6 h and of mdr1b after 24 h. 
In contrast, the P-gp activity was decreased after TNF-α treatment for 48 and 72 h 
(Theron et al. 2003). This controversial finding might be caused by differences between 
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species. For P-gp, Bauer et al. found an up-regulated expression in isolated rat brain 
capillaries after treatment with low concentrations of TNF-α. Whereas P-gp activity was 
reduced for the first 4 h of the treatment, a 2-fold increase in the activity was measured 
after 6 h of TNF-α exposure, accompanied by elevated P-gp protein levels. The authors 
(Bauer et al. 2007) postulated an endothelin-dependent regulation of P-gp and showed 
the involvement of the nitric-oxide synthase (NOS), protein kinase C (PKC) and nuclear 
factor-κB (NFκB) in the down-stream regulation pathway. The induction of P-gp mRNA 
and protein was accompanied by a 2- to 3-fold increase in luminal cyclosporine 
accumulation. Together with these reports our findings indicate that TNF-α may 
increases the expression of P-gp at the BBB. 
TNF-α, IL-1β and IL-6 are early mediators during the inflammatory response. Elevated 
systemic cytokine levels are linked to many diseases during which inflammation occurs, 
such as multiple sclerosis, bacterial meningitis, Alzheimer’s disease and Parkinson’s 
disease. The cytokines can either be released by cells of the CNS or can reach the 
BCECs from the systemic circulation.  
In a cell BBB culture model using primary rat BCECs, TNF-α, IL-1β and IL-6 were shown 
to disrupt the integrity of the BBB in a dose-dependent manner. However, those 
cytokines did not disturb the monolayer tightness in their model, when doses were used 
as in our experiments (de Vries et al. 1996; Forster et al. 2008). Chronically increased 
levels of cytokines could therefore lead to an altered expression of BCRP and P-gp 
without an opening of the BBB.  
Most interestingly, we observed a distinct down-regulation of BCRP mRNA expression 
after treatment with each of the investigated cytokines. Although the effect was not very 
pronounced on the protein level, the accumulation of MX was significantly increased after 
cytokine treatment, indicating a lower transport activity of BCRP. In this study we showed 
for the first time a down-regulation of BCRP expression in an in vitro model of the human 
BBB under influence of IL-1β, IL-6 and TNF-α. Treatment of hCMEC/D3 cells with these 
cytokines decreased BCRP mRNA and protein expression and resulted in a decreased 
BCRP activity. The expression of P-gp was not altered by IL-1β and IL-6 but mRNA and 
protein levels were increased by TNF-α. 
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8.1 Introduction 
A number of peptides released from the gastrointestinal tract have recently been shown 
to regulate appetite and food intake. Peptide YY3-36 (PYY3-36) has been shown to 
induce satiety and to reduce food intake in human and rodents (Batterham et al. 2002; 
Batterham et al. 2003). Glucagon-like peptide-1 (GLP-1) acts mainly as an incretin 
hormone, promoting postprandial insulin release and improving pancreatic β-cell 
function, but it has also been reported to inhibit food intake in humans (Gutzwiller et al. 
1999). Current therapeutic routes of application (subcutaneous injections or nasal 
sprays) do not mimic the physiological release of these hormones. New technologies 
have made it possible to use the oral route as a pathway to deliver large peptides into the 
systemic circulation (Fix 1996; Goldberg and Gomez-Orellana 2003; Ding et al. 2004). 
Up to now, GLP-1 and PYY3-36 have not been administered orally. The aim of this study 
was to evaluate the pharmacological profile and the insulin-releasing activity of 
increasing single oral doses of GLP-1 in healthy male volunteers. We also obtained a 
dose–response curve relating to oral administration of PYY3-36 in healthy male subjects.  
8.2 Methods 
The study was conducted as a phase I, open, placebocontrolled, dose-escalating study. 
Six healthy male subjects were given oral doses of either a placebo or GLP-1 in a dose-
escalating schedule (doses of 0.5, 1.0, 2.0, and 4.0 mg). Next, another group of six 
healthy male subjects were given oral doses of either a placebo or PYY3-36 in the same 
pattern of escalating doses (doses of 0.25, 0.5, 1.0, 2.0, and 4.0 mg). Peptide tablets 
were prepared mixing either GLP-1 or PYY3-36 with 200 mg of a new delivery agent, 
sodium N-[8-(2-hydroxybenzoyl)amino] caprylate (SNAC). 
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8.3 Results 
The lowest dose of GLP-1 did not produce a relevant pharmacokinetic profile (Figure 25) 
Higher oral doses of GLP-1 induced a dose-dependent increase in plasma drug 
concentrations; an exception was the 2 mg dose. Mean plasma drug concentrations 
peaked at between 15 and 30 min after oral administration. For PYY3-36, the absorption 
was rapid, with mean plasma drug concentrations peaking between 15 and 17.5 min 
after administration Figure 25. For GLP-1, the absolute bioavailability could be calculated 
from the oral and intravenous routes of administration and ranged from 1.0 to 9.8%; the 
bioavailability was not dose dependent.  
 
Figure 25 Plasma kinetics of glucagon-like peptide (GLP-1) (left figure). Plasma concentrations of 
GLP-1 after oral administration of increasing doses of GLP-1. n = 6. Plasma concentrations of 
peptide YY3-36 (PYY3-36) (right figure) after oral administration of increasing doses of PYY3-36. 
n = 6. Data represent means ± SEM. 
Furthermore, orally administered GLP-1 at doses higher than 0.5 mg stimulated insulin 
release significantly. Insulin release peaked at ~45–77 min after oral drug administration. 
Orally administered GLP-1 also exhibited a dose-dependent trend for inhibition of ghrelin 
secretion. The inhibition of ghrelin release was observed to last for ~60 min after oral 
administration of the GLP-1 peptide at doses higher than 0.5 mg. Orally administered 
PYY3-36 exhibited a dose-dependent clear trend for inhibition of ghrelin secretion. As in 
the case of GLP-1, for PYY3-36 also, the trend of inhibition of ghrelin secretion appears 
to correlate well with the plasma concentrations of the administered peptide.  
Beside brief phases of nausea and/or abdominal discomfort and 2 episodes of vomiting 
at higher doses, both peptides were well tolerated.  
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8.4 Discussion 
The pharmacokinetics of both peptides, reveal several important aspects. The peptides 
are readily absorbed from the gastrointestinal tract, with peak concentrations achieved 
on average within 15–35 min after the oral dose. A mean absolute bioavailability of 4% 
(range 1–9.8%) was reached relative to intravenous administration of GLP-1. The mean 
peak concentrations in plasma after the highest dose of GLP-1 (4.0 mg) were several 
times higher after oral administration than after intravenous administration. The plasma 
concentrations obtained after higher oral doses of GLP-1 are therefore clearly 
pharmacological concentrations and should be further explored therapeutically. The 
mean peak PYY concentrations in plasma after oral doses of PYY3-36 >0.5 mg produced 
plasma levels that were above those seen after a 1,500 kcal meal in a cohort of 50 
healthy subjects (CB, JD, unpublished data). The plasma concentrations obtained after 
these oral doses of PYY3-36 are therefore clearly pharmacological concentrations with 
potential for therapeutic application. The potential clinical applications of oral GLP-1 
include therapy for type 2 diabetes and obesity, whereas PYY3-36 could lead to 
reduction in food intake and promote weight loss.  
Macromolecules, especially peptides, have a low oral bioavailability because of their 
molecular size and physicochemical characteristics and the rapid degradation by 
digestive enzymes in the gastrointestinal tract (Woodley 1994; Bernkop-Schnurch and 
Walker 2001; Gomez-Orellana 2005). Recently, the delivery agent–based approach has 
been proposed to overcome some of these problems. The technology is based on the 
development of small organic molecules, termed “carriers”, that interact noncovalently 
with macromolecules to enable their oral absorption. In this study, the peptides were 
mixed with the delivery agent SNAC to transport the peptides across the intestinal 
epithelium. SNAC binds noncovalently to the two peptides, thereby increasing their 
lipophilicity. These interactions are reversible, enabling the carrier molecule and the drug 
to dissociate readily after absorption by dilution in the bloodstream (Goldberg and 
Gomez-Orellana 2003).  
In summary, both intravenous GLP-1 and PYY3-36 have been shown to reduce appetite 
and food intake in healthy volunteers and in patients with obesity and/or type 2 diabetes. 
However, intravenous or subcutaneous administration is cumbersome and impractical for 
long-term treatment regimens; the pharmacokinetic profiles of the two peptides obtained 
in this study suggest that the oral route of administration is very promising and could 
overcome the problems associated with intravenous administration. Whether oral GLP-1 
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or oral PYY3-36 administrations are beneficial in different clinical applications remains to 
be shown. Protocols are being developed that will specifically address these questions. 
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9 Conclusion and outlook 
CNS-acting drugs represent a considerable part of all drugs today. During drug 
development the distribution of a drug into the brain needs to be assessed. The BBB 
forms the main obstacle and prevents a broad range of compounds from entering the 
brain tissue. Small hydrophobic compounds are unable to cross the barrier and depend 
on active uptake processes whereas many lipophilic drugs, which could cross the 
membrane passively, are the substrates of efflux transporters. Therefore, in order to 
predict brain penetration of new drug candidates an in vitro model of the human BBB 
would be of great use. 
In this thesis the human brain capillary endothelial cell line hCMEC/D3 was investigated 
in terms of its permeability properties and gene regulation. We found that the hCMEC/D3 
cell line allows to discriminate between compounds with low paracellular and such with 
high transcellular permeability. Under improved conditions the paracellular flux of 
comounds could even be reduced. Furthermore, the expression and functional activity of 
important ABC-transporters was shown in the hCMEC/D3 cells. In addition, it could also 
be demonstrated that the permeability of hCMEC/D3 monolayers could be modulated by 
endo- and exogenous factors. In further studies, altered expression and activity of the 
ABC-transporters BCRP and P-gp in response to pro-inflammatory cytokines was 
observed. 
Based on these findings, the hCEMC/D3 cell line is an interesting in vitro model of the 
human BBB, offering a variety of possible applications: 
• The transport of drugs through the BBB in vitro can be studied using the hCMEC/D3 
cell line. Compared to other BBB in vitro cell lines, the paracellular tightness of the 
hCMEC/D3 cells is higher. However, bidirectional active transport was only observed 
under improved culture conditions. Therefore, the use of the hCMEC/D3 cell line is 
limited to mechanistic studies rather than for high throughput screenings.  
• This model can be used for drug accumulation and efflux studies since important 
transport systems are expressed and active in the hCMEC/D3 cell line. Compared to 
transporter-over-expressing cell lines, the activity of the transporters in the 
hCMEC/D3 cells is low. However, the cells not only express single but a multitude of 
transporters, simulating the complex situation of the BBB. Therefore, this system 
might allow detecting interactions between different transport processes. 
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• The influence of exo- and endogenous factors on the barrier functions of the 
hCMEC/D3 cells can be studied. Since a breakdown of the BBB is observed during a 
multitude of diseases, the hCMEC/D3 cell line can serve as a mechanistic tool in 
order to simulate pathological alterations.  
• Gene regulation can be studied in the hCMEC/D3 cell line. This offers the opportunity 
to determine the expression levels and activities of target genes and proteins during 
simulated states of diseases or under influence of applied drugs. Furthermore, 
signaling experiments can be performed. 
• The hCMEC/D3 cells as model of the human BBB in order to apply targeting 
techniques. As it was shown that the hCMEC/D3 cells express the human transferrin 
receptor, it could be possible to transfer drugs by a targeting vector across 
hCMEC/D3 monolayers. However, systems suited for targeting experiments need to 
be further evaluated in these cells. 
We conclude that the hCMEC/D3 cell line is a versatile in vitro model of the human BBB 
that can be used for numerous applications as shown in this thesis. Therefore, we hope 
that the hCMEC/D3 cell will be a helpful tool in the field of drug discovery.  
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